ID,Inclusion_Exlusion,Reason,Trial_phase,Trial_number,Trial_name,Tumor,Primary_outcome,PFS_primary_outcome,PFS_Registry,PFS_Protocol,PFS_Prespecified,PFS_Paper,PFS_Inconsistency,PFS_Reason,PFS_Free_comments,PFS_Blndeness,ORR_primary_outcome,ORR_Registry,ORR_Protocol,ORR_Prespecified,ORR_Paper,ORR_Inconsistency,ORR_Reason,ORR_Free_comments,ORR_Blndeness,Response_PFS,Response_ORR,title,journal,IF,year,authors,url,pubmed_id
2,Inclusion,,Phase 2,Not available,No name,Gastric and Gastroesophageal Junction Adenocarcinoma,ORR,No,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",Yes,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",,,A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas.,Medicine,1.89,2021,Ni L and Zhang W and Chen Y and Leng W and Gou H and Hu J and Qiu M,https://pubmed.ncbi.nlm.nih.gov/33907099/,33907099
3,Inclusion,,Phase 2,"UMIN000009886	",JBCRG‐19,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).,International journal of clinical oncology,3.4,2021,Aogi K and Watanabe K and Kitada M and Sangai T and Ohtani S and Aruga T and Kawagichi H and Fujisawa T and Maeda S and Morimoto T and Sato N and Takao S and Morita S and Masuda N and Toi M and Ohno S,https://pubmed.ncbi.nlm.nih.gov/33891194/,33891194
4,Inclusion,,Phase 3,NCT02574455,ASCENT,Breast cancer,PFS,Yes,Only central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,,,Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.,The New England journal of medicine,91.25,2021,Bardia A and Hurvitz SA and Tolaney SM and Loirat D and Punie K and Oliveira M and Brufsky A and Sardesai SD and Kalinsky K and Zelnak AB and Weaver R and Traina T and Dalenc F and Aftimos P and Lynce F and Diab S and Cortｾｽｩs J and O'Shaughnessy J and Diｾｽｩras V and Ferrario C and Schmid P and Carey LA and Gianni L and Piccart MJ and Loibl S and Goldenberg DM and Hong Q and Olivo MS and Itri LM and Rugo HS,https://pubmed.ncbi.nlm.nih.gov/33882206/,33882206
5,Inclusion,,Phase 2,NCT02254785,No name,Prostate cancer,Clinical benefit rate,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Annala M and Fu S and Bacon JVW and Sipola J and Iqbal N and Ferrario C and Ong M and Wadhwa D and Hotte SJ and Lo G and Tran B and Wood LA and Gingerich JR and North SA and Pezaro CJ and Ruether JD and Sridhar SS and Kallio HML and Khalaf DJ and Wong A and Beja K and Schｾｽｶnlau E and Taavitsainen S and Nykter M and Vandekerkhove G and Azad AA and Wyatt AW and Chi KN,https://pubmed.ncbi.nlm.nih.gov/33836265/,33836265
6,Exclusion,Outcome,,,,,,,,,,,,,,,,,,,,,,,,,,"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.",The Lancet. Oncology,41.32,2021,Andre T and Amonkar M and Norquist JM and Shiu KK and Kim TW and Jensen BV and Jensen LH and Punt CJA and Smith D and Garcia-Carbonero R and Sevilla I and De La Fouchardiere C and Rivera F and Elez E and Diaz LA Jr and Yoshino T and Van Cutsem E and Yang P and Farooqui M and Le DT,https://pubmed.ncbi.nlm.nih.gov/33812497/,33812497
7,Inclusion,,Phase 3,NCT01926236,ABC-06,Biliary tract cancer,OS,No,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.",The Lancet. Oncology,41.32,2021,Lamarca A and Palmer DH and Wasan HS and Ross PJ and Ma YT and Arora A and Falk S and Gillmore R and Wadsley J and Patel K and Anthoney A and Maraveyas A and Iveson T and Waters JS and Hobbs C and Barber S and Ryder WD and Ramage J and Davies LM and Bridgewater JA and Valle JW,https://pubmed.ncbi.nlm.nih.gov/33798493/,33798493
8,Inclusion,,Phase 3,CTRI/2016/12/007605,No name,Non-small cell lung cancer,PFS,Yes,Unclear,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only blinded",No,Unclear,Only central,Only central,Unclear,Central or local in advance but unclear in paper,,,"Probably, only blinded",Only non-blinded,Only non-blinded,An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer.,Oncology,2.94,2021,Yadav A and Malik PS and Khurana S and Jain D and Vishnubhatla S and Yadav M and Pathy S and Mohan A and Kumar L,https://pubmed.ncbi.nlm.nih.gov/33735884/,33735884
9,Inclusion,,Phase 2,NCT02268695,GORTEC 2014-01 TPExtreme,Head and Neck Cancer,OS,No,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Only central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,,,"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.",The Lancet. Oncology,41.32,2021,Guigay J and Aupｾｽｩrin A and Fayette J and Saada-Bouzid E and Lafond C and Taberna M and Geoffrois L and Martin L and Capitain O and Cupissol D and Castanie H and Vansteene D and Schafhausen P and Johnson A and Even C and Sire C and Duplomb S and Evrard C and Delord JP and Laguerre B and Zanetta S and Chevassus-Clｾｽｩment C and Fraslin A and Louat F and Sinigaglia L and Keilholz U and Bourhis J and Mesia R,https://pubmed.ncbi.nlm.nih.gov/33684370/,33684370
10,Inclusion,,Phase 3,NCT02555657,KEYNOTE-119,Breast cancer,OS,No,Only central,Only central,Only central,Only central,Consistent,,,Only blinded,No,Only central,Only central,Only central,Only central,Consistent,,,Only blinded,,,"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.",The Lancet. Oncology,41.32,2021,Winer EP and Lipatov O and Im SA and Goncalves A and Muｾｽｱoz-Couselo E and Lee KS and Schmid P and Tamura K and Testa L and Witzel I and Ohtani S and Turner N and Zambelli S and Harbeck N and Andre F and Dent R and Zhou X and Karantza V and Mejia J and Cortes J,https://pubmed.ncbi.nlm.nih.gov/33676601/,33676601
11,Inclusion,,Phase 3,NCT02631876,FORWARD I,Ovarian cancer,PFS,Yes,Investigator + central,No protocol,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Only central,No protocol,Only central,Investigator + central,Central or local in advance but both in paper,,,Non-blinded + blinded,,,"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primaryｾＢnalysis of FORWARD I.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Moore KN and Oza AM and Colombo N and Oaknin A and Scambia G and Lorusso D and Konecny GE and Banerjee S and Murphy CG and Tanyi JL and Hirte H and Konner JA and Lim PC and Prasad-Hayes M and Monk BJ and Pautier P and Wang J and Berkenblit A and Vergote I and Birrer MJ,https://pubmed.ncbi.nlm.nih.gov/33667670/,33667670
12,Inclusion,,Phase 3,NCT03141177,CheckMate 9ER,Renal cell cancer,PFS,Yes,Only central,Investigator + central,Investigator + central,Only central,Suspicious of selective reporting,Contradiction,Investigator and BICR were planned to assess the progression in the protocol.,Only blinded,No,Unclear,Investigator + central,Investigator + central,Only central,Suspicious of selective reporting,Contradiction,Investigator and BICR were planned to assess the progression in the protocol.,Only blinded,,,Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.,The New England journal of medicine,91.25,2021,Choueiri TK and Powles T and Burotto M and Escudier B and Bourlon MT and Zurawski B and Oyervides Juｾｽ｡rez VM and Hsieh JJ and Basso U and Shah AY and Suｾｽ｡rez C and Hamzaj A and Goh JC and Barrios C and Richardet M and Porta C and Kowalyszyn R and Feregrino JP and ｾ⒰ｽｻoｾ⒰ｼｯierek J and Pook D and Kessler ER and Tomita Y and Mizuno R and Bedke J and Zhang J and Maurer MA and Simsek B and Ejzykowicz F and Schwab GM and Apolo AB and Motzer RJ,https://pubmed.ncbi.nlm.nih.gov/33657295/,33657295
13,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.,"Lung cancer (Amsterdam, Netherlands)",5.71,2021,Park K and ｾ･波ｾｽｼroｾｮ埠 M and Vansteenkiste J and Spigel D and Yang JC and Bajars M and Ruisi M and Manitz J and Barlesi F,https://pubmed.ncbi.nlm.nih.gov/33636453/,33636453
14,Inclusion,,Phase 3,NCT02811861,CLEAR,Renal cell cancer,PFS,Yes,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,"Probably, non-blinded + blinded",No,Only central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,"Probably, non-blinded + blinded",,,Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.,The New England journal of medicine,91.25,2021,Motzer R and Alekseev B and Rha SY and Porta C and Eto M and Powles T and Grｾｽｼnwald V and Hutson TE and Kopyltsov E and Mｾｽｩndez-Vidal MJ and Kozlov V and Alyasova A and Hong SH and Kapoor A and Alonso Gordoa T and Merchan JR and Winquist E and Maroto P and Goh JC and Kim M and Gurney H and Patel V and Peer A and Procopio G and Takagi T and Melichar B and Rolland F and De Giorgi U and Wong S and Bedke J and Schmidinger M and Dutcus CE and Smith AD and Dutta L and Mody K and Perini RF and Xing D and Choueiri TK,https://pubmed.ncbi.nlm.nih.gov/33616314/,33616314
15,Inclusion,,Phase 2,NCT01630083,FAST,Gastric and Gastroesophageal Junction Adenocarcinoma,OS and PFS,Yes,Only central,No protocol,Only central,Investigator + central,Central or local in advance but both in paper,,,"Probably, non-blinded + blinded",No,Only investigator,No protocol,Only investigator,Investigator + central,Central or local in advance but both in paper,,,"Probably, non-blinded + blinded",,,FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Sahin U and Tｾｽｼreci ｾ and Manikhas G and Lordick F and Rusyn A and Vynnychenko I and Dudov A and Bazin I and Bondarenko I and Melichar B and Dhaene K and Wiechen K and Huber C and Maurus D and Arozullah A and Park JW and Schuler M and Al-Batran SE,https://pubmed.ncbi.nlm.nih.gov/33610734/,33610734
16,Inclusion,,Phase 3,NCT03088540,EMPOWER-Lung 1,Non-small cell lung cancer,OS and PFS,Yes,Only central,Only central,Only central,Only central,Consistent,,,Only blinded,No,Unclear,Only central,Only central,Only central,Consistent,,,Only blinded,,,"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.","Lancet (London, England)",79.32,2021,Sezer A and Kilickap S and Gｾｽｼmｾｽｼｾ M and Bondarenko I and ｾ･波ｾｽｼroｾｮ埠 M and Gogishvili M and Turk HM and Cicin I and Bentsion D and Gladkov O and Clingan P and Sriuranpong V and Rizvi N and Gao B and Li S and Lee S and McGuire K and Chen CI and Makharadze T and Paydas S and Nechaeva M and Seebach F and Weinreich DM and Yancopoulos GD and Gullo G and Lowy I and Rietschel P,https://pubmed.ncbi.nlm.nih.gov/33581821/,33581821
17,Exclusion,Outcome,,,,,,,,,,,,,,,,,,,,,,,,,,Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.,"Lancet (London, England)",79.32,2021,Langley RE and Gilbert DC and Duong T and Clarke NW and Nankivell M and Rosen SD and Mangar S and Macnair A and Sundaram SK and Laniado ME and Dixit S and Madaan S and Manetta C and Pope A and Scrase CD and Mckay S and Muazzam IA and Collins GN and Worlding J and Williams ST and Paez E and Robinson A and McFarlane J and Deighan JV and Marshall J and Forcat S and Weiss M and Kockelbergh R and Alhasso A and Kynaston H and Parmar M,https://pubmed.ncbi.nlm.nih.gov/33581820/,33581820
18,Inclusion,,Phase 3,NCT03080805,PHOEBE,Breast cancer,PFS,Yes,Unclear,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Unclear,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,,,"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.",The Lancet. Oncology,41.32,2021,Xu B and Yan M and Ma F and Hu X and Feng J and Ouyang Q and Tong Z and Li H and Zhang Q and Sun T and Wang X and Yin Y and Cheng Y and Li W and Gu Y and Chen Q and Liu J and Cheng J and Geng C and Qin S and Wang S and Lu J and Shen K and Liu Q and Wang X and Wang H and Luo T and Yang J and Wu Y and Yu Z and Zhu X and Chen C and Zou J,https://pubmed.ncbi.nlm.nih.gov/33581774/,33581774
19,Inclusion,,Phase 3,NCT03474107,EV-301,Urothelial cancer,OS,No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Unclear,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.,The New England journal of medicine,91.25,2021,Powles T and Rosenberg JE and Sonpavde GP and Loriot Y and Durｾｽ｡n I and Lee JL and Matsubara N and Vulsteke C and Castellano D and Wu C and Campbell M and Matsangou M and Petrylak DP,https://pubmed.ncbi.nlm.nih.gov/33577729/,33577729
20,Inclusion,,Phase 3,NCT02481830,CheckMate 331,Small cell lung cancer,OS,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(隨).,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Spigel DR and Vicente D and Ciuleanu TE and Gettinger S and Peters S and Horn L and Audigier-Valette C and Pardo Aranda N and Juan-Vidal O and Cheng Y and Zhang H and Shi M and Luft A and Wolf J and Antonia S and Nakagawa K and Fairchild J and Baudelet C and Pandya D and Doshi P and Chang H and Reck M,https://pubmed.ncbi.nlm.nih.gov/33539946/,33539946
21,Inclusion,,Phase 2,NCT02322814,COLET,Breast cancer,ORR,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,Yes,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Brufsky A and Kim SB and Zvirbule ｾ⒰ｽｽ and Eniu A and Mebis J and Sohn JH and Wongchenko M and Chohan S and Amin R and Yan Y and McNally V and Miles D and Loi S,https://pubmed.ncbi.nlm.nih.gov/33539944/,33539944
22,Inclusion,,Phase 3,"NCT01802749, EudraCT 2012-004362-17",MITO16b/MANGO–OV2/ENGOT–ov17,Ovarian cancer,PFS,Yes,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Unclear,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only blinded",,,"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.",The Lancet. Oncology,41.32,2021,Pignata S and Lorusso D and Joly F and Gallo C and Colombo N and Sessa C and Bamias A and Salutari V and Selle F and Frezzini S and De Giorgi U and Pautier P and Bologna A and Orditura M and Dubot C and Gadducci A and Mammoliti S and Ray-Coquard I and Zafarana E and Breda E and Favier L and Ardizzoia A and Cinieri S and Largillier R and Sambataro D and Guardiola E and Lauria R and Pisano C and Raspagliesi F and Scambia G and Daniele G and Perrone F,https://pubmed.ncbi.nlm.nih.gov/33539744/,33539744
24,Inclusion,,Phase 2,NCT02058706,No name,Prostate cancer,prostate-specific antigen (PSA) response rate,No PFS,Unclear,Only investigator,Only investigator,No PFS,Suspicious of selective reporting,Contradiction,PFS and ORR were planned to assess in the protocol.,No PFS,No ORR,Unclear,Unclear,Unclear,No ORR,Suspicious of selective reporting,Contradiction,PFS and ORR were planned to assess in the protocol.,No ORR,Only non-blinded,,Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.,JAMA network open,8.48,2021,Vaishampayan UN and Heilbrun LK and Monk P 3rd and Tejwani S and Sonpavde G and Hwang C and Smith D and Jasti P and Dobson K and Dickow B and Heath EI and Semaan L and Cher ML and Fontana JA and Chinni S,https://pubmed.ncbi.nlm.nih.gov/33496795/,33496795
25,Inclusion,,Phase 3,NCT02899299,CheckMate 743,Malignant pleural mesothelioma,OS,No,Only central,Only central,Only central,Only central,Consistent,,,Only blinded,No,Only central,Only central,Only central,Only central,Consistent,,,Only blinded,,,"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.","Lancet (London, England)",79.32,2021,Baas P and Scherpereel A and Nowak AK and Fujimoto N and Peters S and Tsao AS and Mansfield AS and Popat S and Jahan T and Antonia S and Oulkhouir Y and Bautista Y and Cornelissen R and Greillier L and Grossi F and Kowalski D and Rodrｾｽｭguez-Cid J and Aanur P and Oukessou A and Baudelet C and Zalcman G,https://pubmed.ncbi.nlm.nih.gov/33485464/,33485464
26,Inclusion,,Phase 3,NCT03215706,CheckMate 9LA,Non-small cell lung cancer,OS,No,Only central,No protocol,Only central,Investigator + central,Central or local in advance but both in paper,,data not shown,Non-blinded + blinded,No,Only central,No protocol,Only central,Only central,Consistent,,,Only blinded,,,"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.",The Lancet. Oncology,41.32,2021,Paz-Ares L and Ciuleanu TE and Cobo M and Schenker M and Zurawski B and Menezes J and Richardet E and Bennouna J and Felip E and Juan-Vidal O and Alexandru A and Sakai H and Lingua A and Salman P and Souquet PJ and De Marchi P and Martin C and Pｾｽｩrol M and Scherpereel A and Lu S and John T and Carbone DP and Meadows-Shropshire S and Agrawal S and Oukessou A and Yan J and Reck M,https://pubmed.ncbi.nlm.nih.gov/33476593/,33476593
28,Inclusion,,Phase 2,NCT02299999,SAFIR02-BREAST IMMUNO trial,Breast cancer,PFS,Yes,Unclear,Only investigator,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",No,Unclear,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.,Nature medicine,53.44,2021,Bachelot T and Filleron T and Bieche I and Arnedos M and Campone M and Dalenc F and Coussy F and Sablin MP and Debled M and Lefeuvre-Plesse C and Goncalves A and Reynier MM and Jacot W and You B and Barthelemy P and Verret B and Isambert N and Tchiknavorian X and Levy C and Thery JC and L'Haridon T and Ferrero JM and Mege A and Del Piano F and Rouleau E and Tran-Dien A and Adam J and Lusque A and Jimenez M and Jacquet A and Garberis I and Andre F,https://pubmed.ncbi.nlm.nih.gov/33462450/,33462450
29,Inclusion,,Phase 3,NCT02028507,PEARL,Breast cancer,PFS,Yes,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Martin M and Zielinski C and Ruiz-Borrego M and Carrasco E and Turner N and Ciruelos EM and Muｾｽｱoz M and Bermejo B and Margeli M and Anton A and Kahan Z and Csｾｽｶszi T and Casas MI and Murillo L and Morales S and Alba E and Gal-Yam E and Guerrero-Zotano A and Calvo L and de la Haba-Rodriguez J and Ramos M and Alvarez I and Garcia-Palomo A and Huang Bartlett C and Koehler M and Caballero R and Corsaro M and Huang X and Garcia-Sｾｽ｡enz JA and Chacｾｽｳn JI and Swift C and Thallinger C and Gil-Gil M,https://pubmed.ncbi.nlm.nih.gov/33385521/,33385521
30,Inclusion,,Unclear,Not available,No name,Colorectal cancer,PFS,Yes,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",No ORR,No registry,No protocol,Not available,No ORR,Not prespecified,,,No ORR,,,Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients.,Medicine,1.89,2020,Geng R and Wang G and Qiu L and Liu B and Yang F and Zhang J and Miao Y,https://pubmed.ncbi.nlm.nih.gov/33371122/,33371122
31,Inclusion,,Phase 3,NCT03134872,CameL,Non-small cell lung cancer,PFS,Yes,Only investigator,No protocol,Only investigator,Investigator + central,Central or local in advance but both in paper,,,Non-blinded + blinded,No,Unclear,No protocol,Unclear,Investigator + central,Unclear in advance but clear in paper,,,Non-blinded + blinded,,,"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.",The Lancet. Respiratory medicine,30.7,2021,Zhou C and Chen G and Huang Y and Zhou J and Lin L and Feng J and Wang Z and Shu Y and Shi J and Hu Y and Wang Q and Cheng Y and Wu F and Chen J and Lin X and Wang Y and Huang J and Cui J and Cao L and Liu Y and Zhang Y and Pan Y and Zhao J and Wang L and Chang J and Chen Q and Ren X and Zhang W and Fan Y and He Z and Fang J and Gu K and Dong X and Zhang T and Shi W and Zou J,https://pubmed.ncbi.nlm.nih.gov/33347829/,33347829
32,Inclusion,,Phase 3,NCT02657434,IMpower132,Non-small cell lung cancer,OS and PFS,Yes,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.,Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,15.61,2021,Nishio M and Barlesi F and West H and Ball S and Bordoni R and Cobo M and Longeras PD and Goldschmidt J Jr and Novello S and Orlandi F and Sanborn RE and Szalai Z and Ursol G and Mendus D and Wang L and Wen X and McCleland M and Hoang T and Phan S and Socinski MA,https://pubmed.ncbi.nlm.nih.gov/33333328/,33333328
33,Inclusion,,Phase 3,NCT02613507,CheckMate 078,Non-small cell lung cancer,OS,No,Only investigator,No protocol,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).","Lung cancer (Amsterdam, Netherlands)",5.71,2021,Lu S and Wang J and Cheng Y and Mok T and Chang J and Zhang L and Feng J and Tu HY and Wu L and Zhang Y and Luft A and Zhou JY and Ma Z and Lu Y and Hu C and Shi Y and Ying K and Zhong H and Poddubskaya E and Soo RA and Chia YH and Li A and Li A and Wu YL,https://pubmed.ncbi.nlm.nih.gov/33321441/,33321441
34,Inclusion,,Phase 3,NCT03273153,IMspire170,Melanoma,PFS,Yes,Investigator + central,No protocol,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Investigator + central,No protocol,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,,,Cobimetinib plus atezolizumab in BRAF(V600) wild-type melanoma: primary results from the randomized phase III IMspire170 study.,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Gogas H and Drｾｽｩno B and Larkin J and Demidov L and Stroyakovskiy D and Eroglu Z and Francesco Ferrucci P and Pigozzo J and Rutkowski P and Mackiewicz J and Rooney I and Voulgari A and Troutman S and Pitcher B and Guo Y and Yan Y and Castro M and Mulla S and Flaherty K and Arance A,https://pubmed.ncbi.nlm.nih.gov/33309774/,33309774
35,Exclusion,Publication,,,,,,,,,,,,,,,,,,,,,,,,,,"A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations.",Medicine,1.89,2020,Song SY and Ha SJ and Park JH and Park SJ and Shin SH and Oak C and Choi JY and Yoon SW and Kim JA and Yoon SH and Son JW and Kim SJ and Yoo HS,https://pubmed.ncbi.nlm.nih.gov/33285743/,33285743
36,Inclusion,,Phase 3,NCT03043872,CASPIAN,Small cell lung cancer,OS,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.",The Lancet. Oncology,41.32,2021,Goldman JW and Dvorkin M and Chen Y and Reinmuth N and Hotta K and Trukhin D and Statsenko G and Hochmair MJ and ｾ･波ｾｽｼroｾｮ埠 M and Ji JH and Garassino MC and Voitko O and Poltoratskiy A and Ponce S and Verderame F and Havel L and Bondarenko I and Kaｾ⒰ｽｼarnowicz A and Losonczy G and Conev NV and Armstrong J and Byrne N and Thiyagarajah P and Jiang H and Paz-Ares L,https://pubmed.ncbi.nlm.nih.gov/33285097/,33285097
38,Inclusion,,Phase 2,"JapicCTI-111390, JapicCTI-142569",JO25567,Non-small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,"Probably, only blinded",No ORR,Unclear,No protocol,Unclear,No ORR,Suspicious of selective reporting,Contradiction,Reported in primary report,No ORR,Only non-blinded,,Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.,"Lung cancer (Amsterdam, Netherlands)",5.71,2021,Yamamoto N and Seto T and Nishio M and Goto K and Yamamoto N and Okamoto I and Yamanaka T and Tanaka M and Takahashi K and Fukuoka M,https://pubmed.ncbi.nlm.nih.gov/33279874/,33279874
40,Inclusion,,Phase 2,NCT01485848,No name,Ovarian cancer,ORR,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.",Gynecologic oncology,5.48,2021,Chelariu-Raicu A and Nick A and Urban R and Gordinier M and Leuschner C and Bavisotto L and Molin GZD and Whisnant JK and Coleman RL,https://pubmed.ncbi.nlm.nih.gov/33243443/,33243443
41,Inclusion,,Phase 3,NCT03052608,CROWN,Non-small cell lung cancer,PFS,Yes,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,,,First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.,The New England journal of medicine,91.25,2020,Shaw AT and Bauer TM and de Marinis F and Felip E and Goto Y and Liu G and Mazieres J and Kim DW and Mok T and Polli A and Thurm H and Calella AM and Peltz G and Solomon BJ,https://pubmed.ncbi.nlm.nih.gov/33207094/,33207094
42,Exclusion,Patient,,,,,,,,,,,,,,,,,,,,,,,,,,"A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours.",BMC cancer,3.15,2020,Ang YLE and Ho GF and Soo RA and Sundar R and Tan SH and Yong WP and Ow SGW and Lim JSJ and Chong WQ and Soe PP and Tai BC and Wang L and Goh BC and Lee SC,https://pubmed.ncbi.nlm.nih.gov/33203399/,33203399
43,Inclusion,,Phase 2,NCT03636308,No name,Pancreatic cancer,ORR,No,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,Yes,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,"Probably, only blinded",,,Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.,Journal of cancer research and clinical oncology,4.55,2021,Zong Y and Yuan J and Peng Z and Lu M and Wang X and Shen L and Zhou J,https://pubmed.ncbi.nlm.nih.gov/33191450/,33191450
44,Inclusion,,Phase 3,NCT02253459,BG01-1323L,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Investigator + central,Unclear in advance but clear in paper,,Primary: local + central,"Probably, non-blinded + blinded",No,Unclear,No protocol,Unclear,Investigator + central,Unclear in advance but clear in paper,,Primary: local + central,"Probably, only blinded",Only non-blinded,Only non-blinded,"Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Xu B and Sun T and Zhang Q and Zhang P and Yuan Z and Jiang Z and Wang X and Cui S and Teng Y and Hu XC and Yang J and Pan H and Tong Z and Li H and Yao Q and Wang Y and Yin Y and Sun P and Zheng H and Cheng J and Lu J and Zhang B and Geng C and Liu J and Shen K and Yu S and Li H and Tang L and Qiu R,https://pubmed.ncbi.nlm.nih.gov/33188874/,33188874
45,Inclusion,,Phase 2,"UMIN000010443	",The North Japan Lung Cancer Group Trial 1302,Non-small cell lung cancer,ORR,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,Randomized phase II trial of carboplatin遯ｶ+遯ｶ遨斬b-paclitaxel versus cisplatin遯ｶ+遯ｶ譖ｳemcitabine for chemotherapy-naｾｽｯve squamous cell carcinoma: North Japan lung cancer study group 1302.,International journal of clinical oncology,3.4,2021,Kawashima Y and Harada T and Fujita Y and Nakagawa T and Watanabe K and Morikawa N and Takamura K and Kanazawa K and Kuda T and Usui K and Sekine A and Inoue A and Sugawara S,https://pubmed.ncbi.nlm.nih.gov/33184754/,33184754
46,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,"Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.",Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,15.61,2021,Fan Y and Zhao J and Wang Q and Huang D and Li X and Chen J and Fang Y and Duan J and Zhou C and Hu Y and Yang H and Hu Y and Zhou J and Lin X and Wang L and Wang Z and Xu Y and Zhang T and Shi W and Zou J and Wang J,https://pubmed.ncbi.nlm.nih.gov/33166719/,33166719
47,Inclusion,,Phase 3,NCT02667743,No name,Non-small cell lung cancer,ORR,No,Unclear,Unclear,Unclear,Investigator + central,Unclear in advance but clear in paper,,,"Probably, non-blinded + blinded",Yes,Only investigator,Unclear,Unclear,Investigator + central,Unclear in advance but clear in paper,,,"Probably, non-blinded + blinded",,,"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2021,Shi M and Gu A and Tu H and Huang C and Wang H and Yu Z and Wang X and Cao L and Shu Y and Wang H and Yang R and Li X and Chang J and Hu Y and Shen P and Hu Y and Guo Z and Tao M and Zhang Y and Liu X and Sun Q and Zhang X and Jiang Z and Zhao J and Chen F and Yu H and Zhang W and Sun J and Li D and Zhou J and Han B and Wu YL,https://pubmed.ncbi.nlm.nih.gov/33130217/,33130217
49,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.,Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,15.61,2021,Awad MM and Gadgeel SM and Borghaei H and Patnaik A and Yang JC and Powell SF and Gentzler RD and Martins RG and Stevenson JP and Altan M and Jalal SI and Panwalkar A and Gubens M and Sequist LV and Saraf S and Zhao B and Piperdi B and Langer CJ,https://pubmed.ncbi.nlm.nih.gov/33069888/,33069888
55,Inclusion,,Phase 3,NCT02409342,IMpower110,Non-small cell lung cancer,OS,No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.,The New England journal of medicine,91.25,2020,Herbst RS and Giaccone G and de Marinis F and Reinmuth N and Vergnenegre A and Barrios CH and Morise M and Felip E and Andric Z and Geater S and ｾ･波ｾｽｼroｾｮ埠 M and Zou W and Sandler A and Enquist I and Komatsubara K and Deng Y and Kuriki H and Wen X and McCleland M and Mocci S and Jassem J and Spigel DR,https://pubmed.ncbi.nlm.nih.gov/32997907/,32997907
56,Inclusion,,Phase 2b,NCT01630018,No name,Ovarian cancer,ORR,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.",British journal of cancer,7.64,2021,Kim HS and Park SY and Park CY and Kim YT and Kim BJ and Song YJ and Kim BG and Kim YB and Cho CH and Kim JH and Song YS,https://pubmed.ncbi.nlm.nih.gov/32994466/,32994466
57,Inclusion,,Phase 3,"NCT02516241, EudraCT number 2015-001633-24",DANUBE,Urothelial cancer,OS,No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.",The Lancet. Oncology,41.32,2020,Powles T and van der Heijden MS and Castellano D and Galsky MD and Loriot Y and Petrylak DP and Ogawa O and Park SH and Lee JL and De Giorgi U and Bｾｽｶgemann M and Bamias A and Eigl BJ and Gurney H and Mukherjee SD and Fradet Y and Skoneczna I and Tsiatas M and Novikov A and Suｾｽ｡rez C and Fay AP and Duran I and Necchi A and Wildsmith S and He P and Angra N and Gupta AK and Levin W and Bellmunt J,https://pubmed.ncbi.nlm.nih.gov/32971005/,32971005
59,Exclusion,Publication,,,,,,,,,,,,,,,,,,,,,,,,,,Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.,The New England journal of medicine,91.25,2020,Hussain M and Mateo J and Fizazi K and Saad F and Shore N and Sandhu S and Chi KN and Sartor O and Agarwal N and Olmos D and Thiery-Vuillemin A and Twardowski P and Roubaud G and ｾ･波ｾｽｼroｾｮ埠 M and Kang J and Burgents J and Gresty C and Corcoran C and Adelman CA and de Bono J,https://pubmed.ncbi.nlm.nih.gov/32955174/,32955174
62,Inclusion,,Phase 3b/4,NCT02066636,CheckMate 153,Non-small cell lung cancer,Safty,No,No PFS,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,No ORR,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2020,Waterhouse DM and Garon EB and Chandler J and McCleod M and Hussein M and Jotte R and Horn L and Daniel DB and Keogh G and Creelan B and Einhorn LH and Baker J and Kasbari S and Nikolinakos P and Babu S and Couture F and Leighl NB and Reynolds C and Blumenschein G Jr and Gunuganti V and Li A and Aanur N and Spigel DR,https://pubmed.ncbi.nlm.nih.gov/32910710/,32910710
67,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer.,Anticancer research,2.48,2020,Madsen CV and Adimi P and Jakobsen A and Steffensen KD,https://pubmed.ncbi.nlm.nih.gov/32878814/,32878814
69,Inclusion,,Unclear,NCT02256800,PURE FIST,Colorectal cancer,PFS,Yes,Unclear,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Unclear,Only investigator,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",,,Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).,"European journal of cancer (Oxford, England : 1990)",9.16,2020,Tsai HL and Huang CW and Lin YW and Wang JH and Wu CC and Sung YC and Chen TL and Wang HM and Tang HC and Chen JB and Ke TW and Tsai CS and Huang HY and Wang JY,https://pubmed.ncbi.nlm.nih.gov/32829105/,32829105
71,Inclusion,,Phase 3,NCT01160211,ALTERNATIVE,Breast cancer,PFS,Yes,Unclear,Investigator + central,Investigator + central,Only investigator,Suspicious of selective reporting,Contradiction,Radiologcal data was planned to be revewed by IRC in the protocol.,Only non-blinded,No,Only investigator,Investigator + central,Investigator + central,Unclear,Suspicious of selective reporting,Contradiction,Radiologcal data was planned to be revewed by IRC in the protocol.,"Probably, only non-blinded",,,"Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2021,Johnston SRD and Hegg R and Im SA and Park IH and Burdaeva O and Kurteva G and Press MF and Tjulandin S and Iwata H and Simon SD and Kenny S and Sarp S and Izquierdo MA and Williams LS and Gradishar WJ,https://pubmed.ncbi.nlm.nih.gov/32822287/,32822287
77,Inclusion,,Unclear,Not available,No name,Non-small cell lung cancer,Unclear,Unclear,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",Unclear,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",,,Study on the Effect of Nano Albumin Paclitaxel Combined with Carboplatin in the Treatment of Lung Squamous Cell Carcinoma.,Journal of nanoscience and nanotechnology,1.13,2020,Wang H and Mou S and Tu M,https://pubmed.ncbi.nlm.nih.gov/32711612/,32711612
78,Exclusion,Publication,,,,,,,,,,,,,,,,,,,,,,,,,,AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.,BMC cancer,3.15,2020,Antoniotti C and Borelli B and Rossini D and Pietrantonio F and Morano F and Salvatore L and Lonardi S and Marmorino F and Tamberi S and Corallo S and Tortora G and Bergamo F and Brunella DS and Boccaccino A and Grassi E and Racca P and Tamburini E and Aprile G and Moretto R and Boni L and Falcone A and Cremolini C,https://pubmed.ncbi.nlm.nih.gov/32698790/,32698790
80,Inclusion,,Phase 3,NCT02322593,SOLAR,Stomach cancer,OS,No,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.",The Lancet. Oncology,41.32,2020,Kang YK and Chin K and Chung HC and Kadowaki S and Oh SC and Nakayama N and Lee KW and Hara H and Chung IJ and Tsuda M and Park SH and Hosaka H and Hironaka S and Miyata Y and Ryu MH and Baba H and Hyodo I and Bang YJ and Boku N,https://pubmed.ncbi.nlm.nih.gov/32682457/,32682457
82,Inclusion,,Phase 3,NCT01808573,NALA,Breast cancer,OS and PFS,Yes,Only central,No protocol,Only central,Investigator + central,Central or local in advance but both in paper,,,Non-blinded + blinded,No,Only central,No protocol,Only central,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",decline,,Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 遶包ｽ･ 2 HER2-Directed Regimens: Phase III NALA Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2020,Saura C and Oliveira M and Feng YH and Dai MS and Chen SW and Hurvitz SA and Kim SB and Moy B and Delaloge S and Gradishar W and Masuda N and Palacova M and Trudeau ME and Mattson J and Yap YS and Hou MF and De Laurentiis M and Yeh YM and Chang HT and Yau T and Wildiers H and Haley B and Fagnani D and Lu YS and Crown J and Lin J and Takahashi M and Takano T and Yamaguchi M and Fujii T and Yao B and Bebchuk J and Keyvanjah K and Bryce R and Brufsky A,https://pubmed.ncbi.nlm.nih.gov/32678716/,32678716
85,Inclusion,,Phase 2,NCT02827201,FIRGEMAX,Pancreatic cancer,PFS,Yes,Unclear,Only investigator,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,Only non-blinded,Only non-blinded,"Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancｾｽｩrologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).","European journal of cancer (Oxford, England : 1990)",9.16,2020,Rinaldi Y and Pointet AL and Khemissa Akouz F and Le Malicot K and Wahiba B and Louafi S and Gratet A and Miglianico L and Laharie H and Bouhier Leporrier K and Thirot Bidault A and Texereau P and Coriat R and Terrebonne E and Gouttebel MC and Malka D and Bachet JB and Lepage C and Taieb J,https://pubmed.ncbi.nlm.nih.gov/32623182/,32623182
91,Exclusion,Intervention,,,,,,,,,,,,,,,,,,,,,,,,,,A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.,Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,15.61,2020,Peters S and Danson S and Hasan B and Dafni U and Reinmuth N and Majem M and Tournoy KG and Mark MT and Pless M and Cobo M and Rodriguez-Abreu D and Falchero L and Moran T and Ortega Granados AL and Monnet I and Mohorcic K and Sureda BM and Betticher D and Demedts I and Macias JA and Cuffe S and Luciani A and Sanchez JG and Curioni-Fontecedro A and Gautschi O and Price G and Coate L and von Moos R and Zielinski C and Provencio M and Menis J and Ruepp B and Pochesci A and Roschitzki-Voser H and Besse B and Rabaglio M and O'Brien MER and Stahel RA,https://pubmed.ncbi.nlm.nih.gov/32565388/,32565388
102,Inclusion,,Phase 3,NCT01481870,CROSS-J-RCC,Renal cell cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,No ORR,No protocol,No ORR,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC.,Clinical genitourinary cancer,2.87,2020,Tomita Y and Naito S and Sassa N and Takahashi A and Kondo T and Koie T and Obara W and Kobayashi Y and Teishima J and Takahashi M and Matsuyama H and Ueda T and Yamaguchi K and Kishida T and Shiroki R and Saika T and Shinohara N and Oya M and Kanayama HO,https://pubmed.ncbi.nlm.nih.gov/32466961/,32466961
103,Exclusion,Publication,,,,,,,,,,,,,,,,,,,,,,,,,,Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).,Journal of cancer research and clinical oncology,4.55,2020,Kurreck A and Geissler M and Martens UM and Riera-Knorrenschild J and Greeve J and Florschｾｽｼtz A and Wessendorf S and Ettrich T and Kanzler S and Nｾｽｶrenberg D and Seidensticker M and Held S and Buechner-Steudel P and Atzpodien J and Heinemann V and Stintzing S and Seufferlein T and Tannapfel A and Reinacher-Schick AC and Modest DP,https://pubmed.ncbi.nlm.nih.gov/32449003/,32449003
105,Inclusion,,Phase 3,NCT03099382,ESCORT,Esophageal Cancer,OS,No,No PFS,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,No ORR,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,Only non-blinded,Only non-blinded,"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.",The Lancet. Oncology,41.32,2020,Huang J and Xu J and Chen Y and Zhuang W and Zhang Y and Chen Z and Chen J and Zhang H and Niu Z and Fan Q and Lin L and Gu K and Liu Y and Ba Y and Miao Z and Jiang X and Zeng M and Chen J and Fu Z and Gan L and Wang J and Zhan X and Liu T and Li Z and Shen L and Shu Y and Zhang T and Yang Q and Zou J,https://pubmed.ncbi.nlm.nih.gov/32416073/,32416073
107,Inclusion,,Phase 2,NCT01642186,No name,Liver cancer,PFS,Yes,Only investigator,No protocol,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.",The oncologist,5.03,2020,El Dika I and Mayer RJ and Venook AP and Capanu M and LaQuaglia MP and Kobos R and O'Neill AF and Chou JF and Ly M and Ang C and O'Reilly EM and Gordan JD and Abou-Alfa GK,https://pubmed.ncbi.nlm.nih.gov/32400000/,32400000
109,Inclusion,,Unclear,Not available,No name,Non-small cell lung cancer,Unclear,Unclear,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",Unclear,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",,,Analysis of Clinical Efficacy of Nano-Albumin Paclitaxel Treatment for Advanced Cell Lung Cancer.,Journal of nanoscience and nanotechnology,1.13,2020,Li X and Zhang Y and Zhi X and Li Y and Qian K,https://pubmed.ncbi.nlm.nih.gov/32384947/,32384947
110,Inclusion,,Phase 2,NCT02870920,The Canadian Cancer Trials Group CO.26 Study,Colorectal cancer,OS,No,Unclear,Only investigator,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",No,Unclear,Only investigator,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",,,Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.,JAMA oncology,31.78,2020,Chen EX and Jonker DJ and Loree JM and Kennecke HF and Berry SR and Couture F and Ahmad CE and Goffin JR and Kavan P and Harb M and Colwell B and Samimi S and Samson B and Abbas T and Aucoin N and Aubin F and Koski SL and Wei AC and Magoski NM and Tu D and O'Callaghan CJ,https://pubmed.ncbi.nlm.nih.gov/32379280/,32379280
113,Inclusion,,Phase 2,NCT01256385,MAESTRO,Head and Neck Cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.",Cancer,6.86,2020,Seiwert TY and Kochanny S and Wood K and Worden FP and Adkins D and Wade JL and Sleckman BG and Anderson D and Brisson RJ and Karrison T and Stadler WM and Vokes EE,https://pubmed.ncbi.nlm.nih.gov/32365226/,32365226
121,Inclusion,,Phase 3,NCT02369874,EAGLE,Head and Neck Cancer,OS,No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2020,Ferris RL and Haddad R and Even C and Tahara M and Dvorkin M and Ciuleanu TE and Clement PM and Mesia R and Kutukova S and Zholudeva L and Daste A and Caballero-Daroqui J and Keam B and Vynnychenko I and Lafond C and Shetty J and Mann H and Fan J and Wildsmith S and Morsli N and Fayette J and Licitra L,https://pubmed.ncbi.nlm.nih.gov/32294530/,32294530
122,Inclusion,,Phase 3,NCT01763671,IFCT-1103 ULTIMATE,Non-small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.,"European journal of cancer (Oxford, England : 1990)",9.16,2020,Cortot AB and Audigier-Valette C and Molinier O and Le Moulec S and Barlesi F and Zalcman G and Dumont P and Pouessel D and Poulet C and Fontaine-Delaruelle C and Hiret S and Dixmier A and Renault PA and Becht C and Raffy O and Dayen C and Mazieres J and Pichon E and Langlais A and Morin F and Moro-Sibilot D and Besse B,https://pubmed.ncbi.nlm.nih.gov/32276179/,32276179
124,Inclusion,,Phase 3,NCT02453282,MYSTIC ,Non-small cell lung cancer,OS and PFS,Yes,Only central,Only central,Only central,Only central,Consistent,,,Only blinded,No,Only central,Only central,Only central,Only central,Consistent,,,Only blinded,,,Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.,JAMA oncology,31.78,2020,Rizvi NA and Cho BC and Reinmuth N and Lee KH and Luft A and Ahn MJ and van den Heuvel MM and Cobo M and Vicente D and Smolin A and Moiseyenko V and Antonia SJ and Le Moulec S and Robinet G and Natale R and Schneider J and Shepherd FA and Geater SL and Garon EB and Kim ES and Goldberg SB and Nakagawa K and Raja R and Higgs BW and Boothman AM and Zhao L and Scheuring U and Stockman PK and Chand VK and Peters S,https://pubmed.ncbi.nlm.nih.gov/32271377/,32271377
129,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,"The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial.",Asian Pacific journal of cancer prevention : APJCP,1.58,2020,Ahmadzadeh A and Seyedian SS and Valizadeh A and Soleimani M and Nazari P and Hamidi H,https://pubmed.ncbi.nlm.nih.gov/32212800/,32212800
130,Inclusion,,Phase 2,UMIN000009297,WJOG7112G (T-ACT Study),Gastric and Gastroesophageal Junction Adenocarcinoma,PFS,Yes,Unclear,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2020,Makiyama A and Sukawa Y and Kashiwada T and Kawada J and Hosokawa A and Horie Y and Tsuji A and Moriwaki T and Tanioka H and Shinozaki K and Uchino K and Yasui H and Tsukuda H and Nishikawa K and Ishida H and Yamanaka T and Yamazaki K and Hironaka S and Esaki T and Boku N and Hyodo I and Muro K,https://pubmed.ncbi.nlm.nih.gov/32208960/,32208960
132,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,"Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ｾ趣ｽｲ and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.",Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,15.61,2020,Paz-Ares L and Kim TM and Vicente D and Felip E and Lee DH and Lee KH and Lin CC and Flor MJ and Di Nicola M and Alvarez RM and Dussault I and Helwig C and Ojalvo LS and Gulley JL and Cho BC,https://pubmed.ncbi.nlm.nih.gov/32173464/,32173464
143,Inclusion,,Phase 2,"EudraCT, 2016–005241–23",No name,Colorectal cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.",The Lancet. Oncology,41.32,2020,Pfeiffer P and Yilmaz M and Mｾｽｶller S and Zitnjak D and Krogh M and Petersen LN and Poulsen Lｾ and Winther SB and Thomsen KG and Qvortrup C,https://pubmed.ncbi.nlm.nih.gov/31999946/,31999946
146,Inclusion,,Phase 3,NCT01627379,POWER,Esophageal Cancer,OS,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2020,Moehler M and Maderer A and Thuss-Patience PC and Brenner B and Meiler J and Ettrich TJ and Hofheinz RD and Al-Batran SE and Vogel A and Mueller L and Lutz MP and Lordick F and Alsina M and Borchert K and Greil R and Eisterer W and Schad A and Slotta-Huspenina J and Van Cutsem E and Lorenzen S,https://pubmed.ncbi.nlm.nih.gov/31959339/,31959339
151,Inclusion,,Phase 3,NCT01909453,COLUMBUS,Melanoma,Unclear,Unclear,Only central,No protocol,Only central,Only central,Consistent,,,"Probably, only blinded",Unclear,Only central,No protocol,Only central,Investigator + central,Central or local in advance but both in paper,,,"Probably, non-blinded + blinded",pending,,Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.,"European journal of cancer (Oxford, England : 1990)",9.16,2020,Ascierto PA and Dummer R and Gogas HJ and Flaherty KT and Arance A and Mandala M and Liszkay G and Garbe C and Schadendorf D and Krajsova I and Gutzmer R and de Groot JWB and Loquai C and Gollerkeri A and Pickard MD and Robert C,https://pubmed.ncbi.nlm.nih.gov/31901705/,31901705
164,Inclusion,,Phase 2,NCT01217034,TACTICS,Liver cancer,OS and PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.",Gut,23.06,2020,Kudo M and Ueshima K and Ikeda M and Torimura T and Tanabe N and Aikata H and Izumi N and Yamasaki T and Nojiri S and Hino K and Tsumura H and Kuzuya T and Isoda N and Yasui K and Aino H and Ido A and Kawabe N and Nakao K and Wada Y and Yokosuka O and Yoshimura K and Okusaka T and Furuse J and Kokudo N and Okita K and Johnson PJ and Arai Y,https://pubmed.ncbi.nlm.nih.gov/31801872/,31801872
166,Inclusion,,Phase 2,NCT00204568,No name,Soft-tissue sarcoma,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma.,"European journal of cancer (Oxford, England : 1990)",9.16,2020,Hartmann JT and Kopp HG and Gruenwald V and Piperno-Neumann S and Kunitz A and Hofheinz R and Mueller L and Geissler M and Horger M and Fix P and Chemnitz JM and Neise M and Wehler T and Zander I and Eckert R and Hann von Weyhern C and Bauer S and Mayer F,https://pubmed.ncbi.nlm.nih.gov/31785463/,31785463
168,Exclusion,Outcome,,,,,,,,,,,,,,,,,,,,,,,,,,"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.",The New England journal of medicine,91.25,2020,Ramalingam SS and Vansteenkiste J and Planchard D and Cho BC and Gray JE and Ohe Y and Zhou C and Reungwetwattana T and Cheng Y and Chewaskulyong B and Shah R and Cobo M and Lee KH and Cheema P and Tiseo M and John T and Lin MC and Imamura F and Kurata T and Todd A and Hodge R and Saggese M and Rukazenkov Y and Soria JC,https://pubmed.ncbi.nlm.nih.gov/31751012/,31751012
173,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial.,Thoracic cancer,3.5,2020,Lee GW and Go SI and Kim DW and Kim HG and Kim JH and An HJ and Jang JS and Kim BS and Hahn S and Heo DS,https://pubmed.ncbi.nlm.nih.gov/31707767/,31707767
174,Inclusion,,Phase 2,NCT01730677,KCSG BR11-16,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2遯ｶ+遯ｶ逶etastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).,British journal of cancer,7.64,2019,Sim SH and Park IH and Jung KH and Kim SB and Ahn JH and Lee KH and Im SA and Im YH and Park YH and Sohn J and Kim YJ and Lee S and Kim HJ and Chae YS and Park KH and Nam BH and Lee KS and Ro J,https://pubmed.ncbi.nlm.nih.gov/31690831/,31690831
177,Inclusion,,Phase 1b/2,NCT02340975,No name,Gastric and Gastroesophageal Junction Adenocarcinoma,PFS and ORR,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.,Clinical cancer research : an official journal of the American Association for           Cancer Research,12.53,2020,Kelly RJ and Lee J and Bang YJ and Almhanna K and Blum-Murphy M and Catenacci DVT and Chung HC and Wainberg ZA and Gibson MK and Lee KW and Bendell JC and Denlinger CS and Chee CE and Omori T and Leidner R and Lenz HJ and Chao Y and Rebelatto MC and Brohawn PZ and He P and McDevitt J and Sheth S and Englert JM and Ku GY,https://pubmed.ncbi.nlm.nih.gov/31676670/,31676670
178,Inclusion,,Phase 2,NCT02592746,KCSG-BR15-10,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,No ORR,No protocol,No ORR,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.",The Lancet. Oncology,41.32,2019,Park YH and Kim TY and Kim GM and Kang SY and Park IH and Kim JH and Lee KE and Ahn HK and Lee MH and Kim HJ and Kim HJ and Lee JI and Koh SJ and Kim JY and Lee KH and Sohn J and Kim SB and Ahn JS and Im YH and Jung KH and Im SA,https://pubmed.ncbi.nlm.nih.gov/31668850/,31668850
185,Inclusion,,Phase 3,NCT00588770,No name,Head and Neck Cancer,OS,No,Unclear,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2019,Argiris A and Li S and Savvides P and Ohr JP and Gilbert J and Levine MA and Chakravarti A and Haigentz M Jr and Saba NF and Ikpeazu CV and Schneider CJ and Pinto HA and Forastiere AA and Burtness B,https://pubmed.ncbi.nlm.nih.gov/31618129/,31618129
189,Inclusion,,Phase 3,NCT03043872,CASPIAN,Small cell lung cancer,OS,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.","Lancet (London, England)",79.32,2019,Paz-Ares L and Dvorkin M and Chen Y and Reinmuth N and Hotta K and Trukhin D and Statsenko G and Hochmair MJ and ｾ･波ｾｽｼroｾｮ埠 M and Ji JH and Voitko O and Poltoratskiy A and Ponce S and Verderame F and Havel L and Bondarenko I and Kazarnowicz A and Losonczy G and Conev NV and Armstrong J and Byrne N and Shire N and Jiang H and Goldman JW,https://pubmed.ncbi.nlm.nih.gov/31590988/,31590988
192,Inclusion,,Phase 3,NCT02485691,CARD,Prostate cancer,PFS,Yes,Unclear,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Unclear,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.,The New England journal of medicine,91.25,2019,de Wit R and de Bono J and Sternberg CN and Fizazi K and Tombal B and Wｾｽｼlfing C and Kramer G and Eymard JC and Bamias A and Carles J and Iacovelli R and Melichar B and Sverrisdｾｽｳttir ｾ and Theodore C and Feyerabend S and Helissey C and Ozatilgan A and Geffriaud-Ricouard C and Castellano D,https://pubmed.ncbi.nlm.nih.gov/31566937/,31566937
193,Inclusion,,Phase 3,NCT02928224,BEACON CRC,Colorectal cancer,OS and ORR,No,Investigator + central,Investigator + central,Investigator + central,Only central,Suspicious of selective reporting,Contradiction,PFS and ORR were planned to assess by investigator and BICR in the registry and the protocol.,Only blinded,Yes,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,pending,,"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.",The New England journal of medicine,91.25,2019,Kopetz S and Grothey A and Yaeger R and Van Cutsem E and Desai J and Yoshino T and Wasan H and Ciardiello F and Loupakis F and Hong YS and Steeghs N and Guren TK and Arkenau HT and Garcia-Alfonso P and Pfeiffer P and Orlov S and Lonardi S and Elez E and Kim TW and Schellens JHM and Guo C and Krishnan A and Dekervel J and Morris V and Calvo Ferrandiz A and Tarpgaard LS and Braun M and Gollerkeri A and Keir C and Maharry K and Pickard M and Christy-Bittel J and Anderson L and Sandor V and Tabernero J,https://pubmed.ncbi.nlm.nih.gov/31566309/,31566309
198,Inclusion,,Phase 2,NCT01735071,No name,Ovarian cancer,PFS and AE,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,"Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.",British journal of cancer,7.64,2019,Colombo N and Zaccarelli E and Baldoni A and Frezzini S and Scambia G and Palluzzi E and Tognon G and Lissoni AA and Rubino D and Ferrero A and Farina G and Negri E and Pesenti Gritti A and Galli F and Biagioli E and Rulli E and Poli D and Gerardi C and Torri V and Fossati R and D'Incalci M,https://pubmed.ncbi.nlm.nih.gov/31537908/,31537908
203,Inclusion,,Phase 2,NCT02354131,NSGO-AVANOVA2/ENGOT-ov24,Ovarian cancer,PFS,Yes,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.",The Lancet. Oncology,41.32,2019,Mirza MR and ｾプall Lundqvist E and Birrer MJ and dePont Christensen R and Nyvang GB and Malander S and Anttila M and Werner TL and Lund B and Lindahl G and Hietanen S and Peen U and Dimoula M and Roed H and ｾ⒋ Knudsen A and Staff S and Krog Vistisen A and Bjｾｽｸrge L and Mｾｽ､enpｾｽ､ｾｽ､ JU,https://pubmed.ncbi.nlm.nih.gov/31474354/,31474354
205,Inclusion,,Phase 2,NCT02422199,No name,Breast cancer,ORR,No,Unclear,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,Yes,Unclear,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,"Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2019,Ma F and Ouyang Q and Li W and Jiang Z and Tong Z and Liu Y and Li H and Yu S and Feng J and Wang S and Hu X and Zou J and Zhu X and Xu B,https://pubmed.ncbi.nlm.nih.gov/31430226/,31430226
207,Inclusion,,Phase 3,CTRI/2016/08/007149,No name,Non-small cell lung cancer,PFS,Yes,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2020,Noronha V and Patil VM and Joshi A and Menon N and Chougule A and Mahajan A and Janu A and Purandare N and Kumar R and More S and Goud S and Kadam N and Daware N and Bhattacharjee A and Shah S and Yadav A and Trivedi V and Behel V and Dutt A and Banavali SD and Prabhash K,https://pubmed.ncbi.nlm.nih.gov/31411950/,31411950
208,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer.,Investigational new drugs,3.85,2020,Luo H and Zhang L and Yang B and Feng Y and Xiong Y and Zhang S and Li X and Qian C and Dong W and Dai N,https://pubmed.ncbi.nlm.nih.gov/31399906/,31399906
212,Inclusion,,Phase 2,UMIN000036556,No name,Non-small cell lung cancer,ORR,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer.,The oncologist,5.03,2019,Takayama K and Ichiki M and Tokunaga S and Inoue K and Kawasaki M and Uchino J and Nakanishi Y,https://pubmed.ncbi.nlm.nih.gov/31332099/,31332099
213,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,"Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.",The Lancet. Oncology,41.32,2019,Toulmonde M and Pulido M and Ray-Coquard I and Andre T and Isambert N and Chevreau C and Penel N and Bompas E and Saada E and Bertucci F and Lebbe C and Le Cesne A and Soulie P and Piperno-Neumann S and Sweet S and Cecchi F and Hembrough T and Bellera C and Kind M and Crombe A and Lucchesi C and Le Loarer F and Blay JY and Italiano A,https://pubmed.ncbi.nlm.nih.gov/31331699/,31331699
215,Inclusion,,Phase 2,NCT01685125,No name,Prostate cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).,Clinical genitourinary cancer,2.87,2019,Dorff TB and Quinn DI and Pinski JK and Goldkorn A and Sadeghi S and Tsao-Wei D and Groshen S and Kuhn P and Gross ME,https://pubmed.ncbi.nlm.nih.gov/31227432/,31227432
222,Inclusion,,Phase 2,NCT00527124,No name,Prostate cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.",The oncologist,5.03,2019,Heath E and Heilbrun L and Mannuel H and Liu G and Lara P and Monk JP and Flaig T and Zurita A and Mack P and Vaishampayan U and Stella P and Smith D and Bolton S and Hussain A and Al-Janadi A and Silbiger D and Usman M and Ivy SP,https://pubmed.ncbi.nlm.nih.gov/31152080/,31152080
224,Inclusion,,Phase 2,UMIN000005487,GOTIC003,Ovarian cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).,International journal of clinical oncology,3.4,2019,Fujiwara H and Ushijima K and Nagao S and Takei Y and Shimada M and Takano M and Yoshino K and Kawano Y and Hirashima Y and Nagase S and Nishio S and Nishikawa T and Ito K and Shoji T and Kimura E and Takano T and Sugiyama T and Kigawa J and Fujiwara K and Suzuki M,https://pubmed.ncbi.nlm.nih.gov/31127479/,31127479
225,Inclusion,,Phase 3,NCT01550055,No name,Colorectal cancer,PFS and ORR,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.","Cancer communications (London, England)",5.1,2019,Shi Y and Li J and Xu J and Sun Y and Wang L and Cheng Y and Liu W and Sun G and Chen Y and Bai L and Zhang Y and He X and Luo Y and Wang Z and Liu Y and Yao Q and Li Y and Qin S and Hu X and Bi F and Zheng R and Ouyang X,https://pubmed.ncbi.nlm.nih.gov/31126331/,31126331
231,Inclusion,,Phase 2,UMIN000008771,LOGIK1201,Non-small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,"Probably, only blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only blinded",Only blinded,Only blinded,Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).,"Lung cancer (Amsterdam, Netherlands)",5.71,2019,Fukuda M and Kitazaki T and Ogawara D and Ichiki M and Mukae H and Maruyama R and Nakagaki N and Shimada M and Ikeda T and Kishimoto J and Harada T and Seto T and Ebi N and Takayama K and Okamoto I and Ichinose Y and Sugio K,https://pubmed.ncbi.nlm.nih.gov/31097081/,31097081
232,Inclusion,,Phase 2,Not available,No name,Non-small cell lung cancer,PFS,Yes,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",No,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",,,An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.,Anticancer research,2.48,2019,Kaira K and Imai H and Souma R and Sakurai R and Miura Y and Sunaga N and Kasahara N and Tsukagoshi Y and Koga Y and Kitahara S and Kotake M and Minato K and Naruse I and Fukushima Y and Hisada T and Ishizuka T,https://pubmed.ncbi.nlm.nih.gov/31092443/,31092443
236,Inclusion,,Phase 3,NCT02256436,KEYNOTE-045,Urothelial cancer,OS and PFS,Yes,Only central,No protocol,Only central,Only central,Consistent,,,Only blinded,No,Only central,No protocol,Only central,Only central,Consistent,,,Only blinded,,,"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2019,Fradet Y and Bellmunt J and Vaughn DJ and Lee JL and Fong L and Vogelzang NJ and Climent MA and Petrylak DP and Choueiri TK and Necchi A and Gerritsen W and Gurney H and Quinn DI and Culine S and Sternberg CN and Nam K and Frenkl TL and Perini RF and de Wit R and Bajorin DF,https://pubmed.ncbi.nlm.nih.gov/31050707/,31050707
239,Inclusion,,Phase 3,NCT01081262,mEOC/GOG 0241,Ovarian cancer,OS,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,"An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.",Gynecologic oncology,5.48,2019,Gore M and Hackshaw A and Brady WE and Penson RT and Zaino R and McCluggage WG and Ganesan R and Wilkinson N and Perren T and Montes A and Summers J and Lord R and Dark G and Rustin G and Mackean M and Reed N and Kehoe S and Frumovitz M and Christensen H and Feeney A and Ledermann J and Gershenson DM,https://pubmed.ncbi.nlm.nih.gov/31005287/,31005287
251,Inclusion,,Phase 2,NCT02072031,No name,Renal cell cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.,The oncologist,5.03,2019,Zhou AP and Bai Y and Song Y and Luo H and Ren XB and Wang X and Shi B and Fu C and Cheng Y and Liu J and Qin S and Li J and Li H and Bai X and Ye D and Wang J and Ma J,https://pubmed.ncbi.nlm.nih.gov/30902918/,30902918
253,Inclusion,,Phase 2,NCT01283204,No name,Stomach cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,No ORR,No protocol,No ORR,Unclear,Unclear in advance but clear in paper,,,"Probably, only non-blinded",Only blinded (radiologist),Only blinded (radiologist),Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.,"European journal of cancer (Oxford, England : 1990)",9.16,2019,Kim C and Chon HJ and Kim JH and Jung M and Nam CM and Kim HS and Kang B and Chung HC and Rha SY,https://pubmed.ncbi.nlm.nih.gov/30901609/,30901609
254,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,"Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2019,Van Cutsem E and Huijberts S and Grothey A and Yaeger R and Cuyle PJ and Elez E and Fakih M and Montagut C and Peeters M and Yoshino T and Wasan H and Desai J and Ciardiello F and Gollerkeri A and Christy-Bittel J and Maharry K and Sandor V and Schellens JHM and Kopetz S and Tabernero J,https://pubmed.ncbi.nlm.nih.gov/30892987/,30892987
256,Inclusion,,Phase 2,NCT01534455,E-VITA,Breast cancer,PFS and tolerability,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).,Anti-cancer drugs,2.25,2019,Bischoff J and Barinoff J and Mundhenke C and Bauerschlag DO and Costa SD and Herr D and Lｾｽｼbbe K and Marmｾｽｩ F and Maass N and von Minckwitz G and Grischke EM and Mｾｽｼller V and Schmidt M and Gerber B and Kｾｽｼmmel S and Schumacher C and Krabisch P and Seiler S and Thill M and Nekljudova V and Loibl S,https://pubmed.ncbi.nlm.nih.gov/30875348/,30875348
257,Inclusion,,Phase 2,"EudraCT, number 2014-000394-39",NORDIC9,Colorectal cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.",The lancet. Gastroenterology & hepatology,14.78,2019,Winther SB and Liposits G and Skuladottir H and Hofsli E and Shah CH and Poulsen Lｾ and Ryg J and Osterlund P and Berglund ｾ and Qvortrup C and Glimelius B and Sorbye H and Pfeiffer P,https://pubmed.ncbi.nlm.nih.gov/30852136/,30852136
258,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.,Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,15.61,2019,Cho BC and Obermannova R and Bearz A and McKeage M and Kim DW and Batra U and Borra G and Orlov S and Kim SW and Geater SL and Postmus PE and Laurie SA and Park K and Yang CT and Ardizzoni A and Bettini AC and de Castro G Jr and Kiertsman F and Chen Z and Lau YY and Viraswami-Appanna K and Passos VQ and Dziadziuszko R,https://pubmed.ncbi.nlm.nih.gov/30851442/,30851442
262,Inclusion,,Phase 2,UMIN000013586,No name,Non-small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer.,"In vivo (Athens, Greece)",2.15,2019,Kitagawa C and Mori M and Ichiki M and Sukoh N and Kada A and Saito AM and Ichinose Y,https://pubmed.ncbi.nlm.nih.gov/30804129/,30804129
264,Inclusion,,Phase 2,NCT01248299,E-DIS,Esophageal Cancer,OS,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,No ORR,No protocol,No ORR,Unclear,Unclear in advance but clear in paper,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).,"European journal of cancer (Oxford, England : 1990)",9.16,2019,Adenis A and Bennouna J and Etienne PL and Bogart E and Francois E and Galais MP and Ben Abdelghani M and Michel P and Metges JP and Dahan L and Conroy T and Ghiringhelli F and Drouillard A and El Hajbi F and Samalin E and Hiret S and Delaine-Clisant S and Mariette C and Penel N and Piessen G and Le Deley MC,https://pubmed.ncbi.nlm.nih.gov/30798084/,30798084
266,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.,Journal of cancer research and clinical oncology,4.55,2019,Schuler M and Tan EH and O'Byrne K and Zhang L and Boyer M and Mok T and Hirsh V and Yang JC and Lee KH and Lu S and Shi Y and Kim SW and Laskin J and Kim DW and Arvis CD and Kｾｽｶlbeck K and Massey D and Mｾｽ､rten A and Paz-Ares L and Park K,https://pubmed.ncbi.nlm.nih.gov/30783814/,30783814
272,Inclusion,,Phase 2,NCT02271464,MOMA,Colorectal cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.,"European journal of cancer (Oxford, England : 1990)",9.16,2019,Cremolini C and Marmorino F and Bergamo F and Aprile G and Salvatore L and Masi G and Dell'Aquila E and Antoniotti C and Murgioni S and Allegrini G and Borelli B and Gemma D and Casagrande M and Granetto C and Delfanti S and Di Donato S and Schirripa M and Sensi E and Tonini G and Lonardi S and Fontanini G and Boni L and Falcone A,https://pubmed.ncbi.nlm.nih.gov/30735919/,30735919
274,Inclusion,,Phase 3,NCT01245062,METRIC,Melanoma,PFS,Yes,Investigator + central,No protocol,Investigator + central,Only investigator,Suspicious of selective reporting,Contradiction,Primary: local + central,Only non-blinded,No,Investigator + central,No protocol,Investigator + central,Only investigator,Suspicious of selective reporting,Contradiction,Primary:only local,Only non-blinded,,,Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600ｾE/K-mutant advanced or metastatic melanoma.,"European journal of cancer (Oxford, England : 1990)",9.16,2019,Robert C and Flaherty K and Nathan P and Hersey P and Garbe C and Milhem M and Demidov L and Mohr P and Hassel JC and Rutkowski P and Dummer R and Utikal J and Kiecker F and Larkin J and D'Amelio A Jr and Mookerjee B and Schadendorf D,https://pubmed.ncbi.nlm.nih.gov/30690294/,30690294
282,Inclusion,,Phase 3,NCT01494506,NAPOLI-1,Pancreatic cancer,OS,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.,"European journal of cancer (Oxford, England : 1990)",9.16,2019,Wang-Gillam A and Hubner RA and Siveke JT and Von Hoff DD and Belanger B and de Jong FA and Mirakhur B and Chen LT,https://pubmed.ncbi.nlm.nih.gov/30654298/,30654298
284,Inclusion,,Phase 2,ChiCTR-IPR-14005583,No name,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study.,Journal of B.U.ON. : official journal of the Balkan Union of Oncology,2.53,2018,Shao B and Song G and Li H and Dil L and Jiang H and Liang X and Yan Y and Zhang R and Ran R and Wang J and Liu X and You M,https://pubmed.ncbi.nlm.nih.gov/30610781/,30610781
286,Exclusion,Intervention,,,,,,,,,,,,,,,,,,,,,,,,,,Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.,"Cancer immunology, immunotherapy : CII",6.97,2019,Chiappori AA and Williams CC and Gray JE and Tanvetyanon T and Haura EB and Creelan BC and Thapa R and Chen DT and Simon GR and Bepler G and Gabrilovich DI and Antonia SJ,https://pubmed.ncbi.nlm.nih.gov/30591959/,30591959
287,Inclusion,,Phase 2,NCT00913835,No name,Ovarian cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Randomized phase II study of the PDGFRｾ趣ｽｱ antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.,BMC cancer,3.15,2018,McGuire WP and Penson RT and Gore M and Herraez AC and Peterson P and Shahir A and Ilaria R Jr,https://pubmed.ncbi.nlm.nih.gov/30591028/,30591028
288,Inclusion,,Phase 2,NCT01716715,No name,Ovarian cancer,PFS,Yes,No PFS,No protocol,No PFS,Unclear,Not prespecified,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.",Gynecologic oncology,5.48,2019,Matulonis UA and Sill MW and Makker V and Mutch DG and Carlson JW and Darus CJ and Mannel RS and Bender DP and Crane EK and Aghajanian C,https://pubmed.ncbi.nlm.nih.gov/30587441/,30587441
292,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.,"European journal of cancer (Oxford, England : 1990)",9.16,2019,von Pawel J and Bordoni R and Satouchi M and Fehrenbacher L and Cobo M and Han JY and Hida T and Moro-Sibilot D and Conkling P and Gandara DR and Rittmeyer A and Gandhi M and Yu W and Matheny C and Patel H and Sandler A and Ballinger M and Kowanetz M and Park K,https://pubmed.ncbi.nlm.nih.gov/30562710/,30562710
293,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.,Endocrine-related cancer,5.68,2019,Hu MI and Elisei R and Dedecjus M and Popovtzer A and Druce M and Kapiteijn E and Pacini F and Locati L and Krajewska J and Weiss R and Gagel RF,https://pubmed.ncbi.nlm.nih.gov/30557850/,30557850
296,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.,"Lung cancer (Amsterdam, Netherlands)",5.71,2018,John T and Akamatsu H and Delmonte A and Su WC and Lee JS and Chang GC and Huang X and Jenkins S and Wu YL,https://pubmed.ncbi.nlm.nih.gov/30527177/,30527177
298,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.,Pediatric blood & cancer,3.17,2019,Moreno L and Vaidya SJ and Schrey D and Pinkerton CR and Lewis IJ and Kearns PR and Machin D and Pearson ADJ,https://pubmed.ncbi.nlm.nih.gov/30516328/,30516328
301,Inclusion,,Phase 3,Not available,GRAPE,Pancreatic cancer,OS,No,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",No,No registry,No protocol,Not available,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).","European journal of cancer (Oxford, England : 1990)",9.16,2019,Ioka T and Ueno M and Ueno H and Park JO and Chang HM and Sasahira N and Kanai M and Chung IJ and Ikeda M and Nakamori S and Mizuno N and Omuro Y and Yamaguchi T and Hara H and Sugimori K and Furuse J and Maguchi H and Furukawa M and Fukuzawa K and Kim JS and Yukisawa S and Takeuchi M and Okusaka T and Boku N and Hyodo I,https://pubmed.ncbi.nlm.nih.gov/30471651/,30471651
302,Inclusion,,Phase 2,ACTRN12612000901808 ,ICECREAM,Colorectal cancer,PFS,Yes,Unclear,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.",Clinical colorectal cancer,4.48,2018,Shapiro JD and Thavaneswaran S and Underhill CR and Robledo KP and Karapetis CS and Day FL and Nott LM and Jefford M and Chantrill LA and Pavlakis N and Tebbutt NC and Price TJ and Khasraw M and Van Hazel GA and Waring PM and Tejpar S and Simes J and Gebski VJ and Desai J and Segelov E,https://pubmed.ncbi.nlm.nih.gov/30463680/,30463680
303,Inclusion,,Phase 3,NCT01704716,HR-NBL1/SIOPEN,Neuroblastoma,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No ORR,No ORR,No protocol,No ORR,No ORR,Consistent,,,No ORR,,,"Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.",The Lancet. Oncology,41.32,2018,Ladenstein R and Pｾｽｶtschger U and Valteau-Couanet D and Luksch R and Castel V and Yaniv I and Laureys G and Brock P and Michon JM and Owens C and Trahair T and Chan GCF and Ruud E and Schroeder H and Beck Popovic M and Schreier G and Loibner H and Ambros P and Holmes K and Castellani MR and Gaze MN and Garaventa A and Pearson ADJ and Lode HN,https://pubmed.ncbi.nlm.nih.gov/30442501/,30442501
305,Inclusion,,Phase 2,EudraCT number 2011-002545-35,PACMEL,Melanoma,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,"Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2019,Urbonas V and Schadendorf D and Zimmer L and Danson S and Marshall E and Corrie P and Wheater M and Plummer E and Mauch C and Scudder C and Goff M and Love SB and Mohammed SB and Middleton MR,https://pubmed.ncbi.nlm.nih.gov/30428063/,30428063
308,Exclusion,Patient,,,,,,,,,,,,,,,,,,,,,,,,,,Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.,"European journal of cancer (Oxford, England : 1990)",9.16,2018,Chen LT and Siveke JT and Wang-Gillam A and Li CP and Bodoky G and Dean AP and Shan YS and Jameson GS and Macarulla T and Lee KH and Cunningham D and Blanc JF and Chiu CF and Schwartsmann G and Braiteh FS and Mamlouk K and Belanger B and de Jong FA and Hubner RA,https://pubmed.ncbi.nlm.nih.gov/30414528/,30414528
313,Exclusion,Patient,,,,,,,,,,,,,,,,,,,,,,,,,,Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.,JAMA oncology,31.78,2019,Falchook G and Coleman RL and Roszak A and Behbakht K and Matulonis U and Ray-Coquard I and Sawrycki P and Duska LR and Tew W and Ghamande S and Lesoin A and Schwartz PE and Buscema J and Fabbro M and Lortholary A and Goff B and Kurzrock R and Martin LP and Gray HJ and Fu S and Sheldon-Waniga E and Lin HM and Venkatakrishnan K and Zhou X and Leonard EJ and Schilder RJ,https://pubmed.ncbi.nlm.nih.gov/30347019/,30347019
323,Exclusion,Outcome,,,,,,,,,,,,,,,,,,,,,,,,,,"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",The Lancet. Oncology,41.32,2018,Dummer R and Ascierto PA and Gogas HJ and Arance A and Mandala M and Liszkay G and Garbe C and Schadendorf D and Krajsova I and Gutzmer R and Chiarion Sileni V and Dutriaux C and de Groot JWB and Yamazaki N and Loquai C and Moutouh-de Parseval LA and Pickard MD and Sandor V and Robert C and Flaherty KT,https://pubmed.ncbi.nlm.nih.gov/30219628/,30219628
324,Exclusion,Patient,,,,,,,,,,,,,,,,,,,,,,,,,,"Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.",Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,15.61,2018,Gandara DR and von Pawel J and Mazieres J and Sullivan R and Helland ｾ and Han JY and Ponce Aix S and Rittmeyer A and Barlesi F and Kubo T and Park K and Goldschmidt J and Gandhi M and Yun C and Yu W and Matheny C and He P and Sandler A and Ballinger M and Fehrenbacher L,https://pubmed.ncbi.nlm.nih.gov/30217492/,30217492
325,Inclusion,,Phase 1/2,NCT01433172,No name,Non-small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Unclear,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.,"Cancer immunology, immunotherapy : CII",6.97,2018,Gray JE and Chiappori A and Williams CC and Tanvetyanon T and Haura EB and Creelan BC and Kim J and Boyle TA and Pinder-Schenck M and Khalil F and Altiok S and Devane R and Noyes D and Mediavilla-Varela M and Smilee R and Hopewell EL and Kelley L and Antonia SJ,https://pubmed.ncbi.nlm.nih.gov/30209589/,30209589
341,Exclusion,Publication,,,,,,,,,,,,,,,,,,,,,,,,,,"An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.",BMC cancer,3.15,2018,Shoji T and Komiyama S and Kigawa J and Tanabe H and Kato K and Itamochi H and Fujiwara H and Kamiura S and Hamano T and Sugiyama T,https://pubmed.ncbi.nlm.nih.gov/30064406/,30064406
342,Inclusion,,Phase 2,Not available,No name,Uterine leiomyosarcoma,PFS,Yes,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",Unclear,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",,,A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.,British journal of cancer,7.64,2018,Gadducci A and Grosso F and Scambia G and Raspagliesi F and Colombo N and Grignani G and Casali P and Sanfilippo R and Buonadonna A and Santoro A and Bruzzone M and Artioli G and Lorusso D and Biagioli E and Fossati R and Galli F and Negri E and Rulli E and Torri V and D'Incalci M,https://pubmed.ncbi.nlm.nih.gov/30057406/,30057406
346,Exclusion,Publication,,,,,,,,,,,,,,,,,,,,,,,,,,"A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.",Japanese journal of clinical oncology,3.02,2018,Yamamoto Y and Iwata H and Ueno T and Taira N and Kashiwaba M and Takahashi M and Tada H and Tsugawa K and Toyama T and Niikura N and Hara F and Fujisawa T and Yoshinami T and Saji S and Takano T and Masuda N and Morita S and Toi M and Ohno S,https://pubmed.ncbi.nlm.nih.gov/30020510/,30020510
349,Inclusion,,Phase 2,NCT02558959,No name,Biliary tract cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,No ORR,No protocol,No ORR,Unclear,Unclear in advance but clear in paper,,,"Probably, only non-blinded",,,A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin.,British journal of cancer,7.64,2018,Zheng Y and Tu X and Zhao P and Jiang W and Liu L and Tong Z and Zhang H and Yan C and Fang W and Wang W,https://pubmed.ncbi.nlm.nih.gov/29955136/,29955136
351,Inclusion,,Phase 3,NCT01287624,CBCSG006,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Unclear,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2018,Zhang J and Lin Y and Sun XJ and Wang BY and Wang ZH and Luo JF and Wang LP and Zhang S and Cao J and Tao ZH and Wu J and Shao ZM and Yang WT and Hu XC,https://pubmed.ncbi.nlm.nih.gov/29905759/,29905759
354,Inclusion,,Phase 3,NCT02370498,KEYNOTE-061,Gastric and Gastroesophageal Junction Adenocarcinoma,OS and PFS,Yes,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,,,"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.","Lancet (London, England)",79.32,2018,Shitara K and ｾ･波ｾｽｼroｾｮ埠 M and Bang YJ and Di Bartolomeo M and Mandalｾ M and Ryu MH and Fornaro L and Olesiｾﾐｳki T and Caglevic C and Chung HC and Muro K and Goekkurt E and Mansoor W and McDermott RS and Shacham-Shmueli E and Chen X and Mayo C and Kang SP and Ohtsu A and Fuchs CS,https://pubmed.ncbi.nlm.nih.gov/29880231/,29880231
360,Inclusion,,Phase 2,NCT00977574,GOG-86P,Endometrial cancer,PFS,Yes,No PFS,No protocol,No PFS,Unclear,Not prespecified,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.",Gynecologic oncology,5.48,2018,Aghajanian C and Filiaci V and Dizon DS and Carlson JW and Powell MA and Secord AA and Tewari KS and Bender DP and O'Malley DM and Stuckey A and Gao J and Dao F and Soslow RA and Lankes HA and Moore K and Levine DA,https://pubmed.ncbi.nlm.nih.gov/29804638/,29804638
365,Exclusion,Intervention,,,,,,,,,,,,,,,,,,,,,,,,,,Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2018,Ishigami H and Fujiwara Y and Fukushima R and Nashimoto A and Yabusaki H and Imano M and Imamoto H and Kodera Y and Uenosono Y and Amagai K and Kadowaki S and Miwa H and Yamaguchi H and Yamaguchi T and Miyaji T and Kitayama J,https://pubmed.ncbi.nlm.nih.gov/29746229/,29746229
376,Inclusion,,Phase 2,NCT01367002,No name,Endometrial cancer,PFS,Yes,Unclear,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,No ORR,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2018,Fader AN and Roque DM and Siegel E and Buza N and Hui P and Abdelghany O and Chambers SK and Secord AA and Havrilesky L and O'Malley DM and Backes F and Nevadunsky N and Edraki B and Pikaart D and Lowery W and ElSahwi KS and Celano P and Bellone S and Azodi M and Litkouhi B and Ratner E and Silasi DA and Schwartz PE and Santin AD,https://pubmed.ncbi.nlm.nih.gov/29584549/,29584549
380,Inclusion,,Phase 3,NCT02231749,CheckMate 214 ,Renal cell cancer,"OS, PFS and ORR",Yes,Only central,Only central,Only central,Only central,Consistent,,,"Probably, only blinded",Yes,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,"Probably, non-blinded + blinded",,,Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.,The New England journal of medicine,91.25,2018,Motzer RJ and Tannir NM and McDermott DF and Arｾｽｩn Frontera O and Melichar B and Choueiri TK and Plimack ER and Barthｾｽｩlｾｽｩmy P and Porta C and George S and Powles T and Donskov F and Neiman V and Kollmannsberger CK and Salman P and Gurney H and Hawkins R and Ravaud A and Grimm MO and Bracarda S and Barrios CH and Tomita Y and Castellano D and Rini BI and Chen AC and Mekan S and McHenry MB and Wind-Rotolo M and Doan J and Sharma P and Hammers HJ and Escudier B,https://pubmed.ncbi.nlm.nih.gov/29562145/,29562145
382,Inclusion,,Phase 2,NCT01835158,CABOSUN,Renal cell cancer,PFS,Yes,Investigator + central,No protocol,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Only investigator,No protocol,Only investigator,Investigator + central,Central or local in advance but both in paper,,,Non-blinded + blinded,,,Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.,"European journal of cancer (Oxford, England : 1990)",9.16,2018,Choueiri TK and Hessel C and Halabi S and Sanford B and Michaelson MD and Hahn O and Walsh M and Olencki T and Picus J and Small EJ and Dakhil S and Feldman DR and Mangeshkar M and Scheffold C and George D and Morris MJ,https://pubmed.ncbi.nlm.nih.gov/29550566/,29550566
387,Inclusion,,Phase 2,NCT00948480,MACVAC,Melanoma,OS,Unclear,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No ORR,No ORR,No protocol,No ORR,No ORR,Consistent,,,No ORR,Only non-blinded,Only non-blinded,Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.,Journal for immunotherapy of cancer,9.91,2018,Dillman RO and Cornforth AN and Nistor GI and McClay EF and Amatruda TT and Depriest C,https://pubmed.ncbi.nlm.nih.gov/29510745/,29510745
392,Inclusion,,Phase 3,NCT01501669,PROCEED,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).,Cancer research and treatment,4.68,2019,Park IH and Im SA and Jung KH and Sohn JH and Park YH and Lee KS and Sim SH and Park KH and Kim JH and Nam BH and Kim HJ and Kim TY and Lee KH and Kim SB and Ahn JH and Lee S and Ro J,https://pubmed.ncbi.nlm.nih.gov/29458237/,29458237
393,Inclusion,,Phase 2,NCT00889382,No name,Ovarian cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.,Gynecologic oncology,5.48,2018,Oza A and Kaye S and Van Tornout J and Sessa C and Gore M and Naumann RW and Hirte H and Colombo N and Chen J and Gorla S and Poondru S and Singh M and Steinberg J and Yuen G and Banerjee S,https://pubmed.ncbi.nlm.nih.gov/29454514/,29454514
394,Inclusion,,Phase 2,NCT00892710,No name,Non-small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.",Cancer,6.86,2018,Spigel DR and Hainsworth JD and Joseph MJ and Shipley DL and Hagan MK and Thompson DS and Burris HA 3rd and Greco FA,https://pubmed.ncbi.nlm.nih.gov/29451696/,29451696
396,Inclusion,,Phase 3,NCT01095003,No name,Breast cancer,PFS,Yes,Only central,No protocol,Only central,Only central,Consistent,,,Only blinded,No,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,Only blinded,,,Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2018,Martin M and Campone M and Bondarenko I and Sakaeva D and Krishnamurthy S and Roman L and Lebedeva L and Vedovato JC and Aapro M,https://pubmed.ncbi.nlm.nih.gov/29447329/,29447329
399,Inclusion,,Phase 2,NCT02083653,Sym004-05,Colorectal cancer,OS,No,Unclear,Only investigator,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",No,Unclear,Only investigator,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",,,Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.,JAMA oncology,31.78,2018,Montagut C and Argilｾｽｩs G and Ciardiello F and Poulsen TT and Dienstmann R and Kragh M and Kopetz S and Lindsted T and Ding C and Vidal J and Clausell-Tormos J and Siravegna G and Sｾｽ｡nchez-Martｾｽｭn FJ and Koefoed K and Pedersen MW and Grandal MM and Dvorkin M and Wyrwicz L and Rovira A and Cubillo A and Salazar R and Desseigne F and Nadal C and Albanell J and Zagonel V and Siena S and Fumi G and Rospo G and Nadler P and Horak ID and Bardelli A and Tabernero J,https://pubmed.ncbi.nlm.nih.gov/29423521/,29423521
400,Inclusion,,Phase 2,NCT01320254,PICCA,Biliary tract cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.,"European journal of cancer (Oxford, England : 1990)",9.16,2018,Vogel A and Kasper S and Bitzer M and Block A and Sinn M and Schulze-Bergkamen H and Moehler M and Pfarr N and Endris V and Goeppert B and Merx K and Schnoy E and Siveke JT and Michl P and Waldschmidt D and Kuhlmann J and Geissler M and Kahl C and Evenkamp R and Schmidt T and Kuhlmann A and Weichert W and Kubicka S,https://pubmed.ncbi.nlm.nih.gov/29413685/,29413685
402,Inclusion,,Phase 2,NCT01991210,No name,Ovarian cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2018,Banerjee S and Oza AM and Birrer MJ and Hamilton EP and Hasan J and Leary A and Moore KN and Mackowiak-Matejczyk B and Pikiel J and Ray-Coquard I and Trask P and Lin K and Schuth E and Vaze A and Choi Y and Marsters JC and Maslyar DJ and Lemahieu V and Wang Y and Humke EW and Liu JF,https://pubmed.ncbi.nlm.nih.gov/29401246/,29401246
403,Inclusion,,Phase 2,NCT01274273,DaRenCa,Renal cell cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Only non-blinded,Only non-blinded,A randomized phase II trial of interleukin-2 and interferon-ｾ趣ｽｱ plus bevacizumab versus interleukin-2 and interferon-ｾ趣ｽｱ in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.,"Acta oncologica (Stockholm, Sweden)",4.09,2018,Donskov F and Jensen NV and Smidt-Hansen T and Brｾｽｸndum L and Geertsen P,https://pubmed.ncbi.nlm.nih.gov/29392960/,29392960
404,Inclusion,,Phase 3,NCT00309985,CHAARTED,Prostate cancer,OS,No,Only investigator,Only investigator,Only investigator,Only investigator,Consistent,,,Only non-blinded,No ORR,No ORR,No ORR,No ORR,No ORR,Consistent,,,No ORR,,,Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2018,Kyriakopoulos CE and Chen YH and Carducci MA and Liu G and Jarrard DF and Hahn NM and Shevrin DH and Dreicer R and Hussain M and Eisenberger M and Kohli M and Plimack ER and Vogelzang NJ and Picus J and Cooney MM and Garcia JA and DiPaola RS and Sweeney CJ,https://pubmed.ncbi.nlm.nih.gov/29384722/,29384722
405,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.",The Lancet. Oncology,41.32,2018,D'Angelo SP and Mahoney MR and Van Tine BA and Atkins J and Milhem MM and Jahagirdar BN and Antonescu CR and Horvath E and Tap WD and Schwartz GK and Streicher H,https://pubmed.ncbi.nlm.nih.gov/29370992/,29370992
406,Exclusion,Publication,,,,,,,,,,,,,,,,,,,,,,,,,,The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.,BMC cancer,3.15,2018,Battaglin F and Schirripa M and Buggin F and Pietrantonio F and Morano F and Boscolo G and Tonini G and Lutrino ES and Lucchetti J and Salvatore L and Passardi A and Cremolini C and Arnoldi E and Scartozzi M and Pella N and Boni L and Bergamo F and Zagonel V and Loupakis F and Lonardi S,https://pubmed.ncbi.nlm.nih.gov/29370781/,29370781
407,Inclusion,,Phase 3,NCT01352117,A5264/AMC-067,Kaposi Sarcoma,PFS,Yes,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,"Probably, only blinded",No,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,"Probably, only blinded",,,As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.,Clinical infectious diseases : an official publication of the Infectious Diseases           Society of America,9.08,2018,Hosseinipour MC and Kang M and Krown SE and Bukuru A and Umbleja T and Martin JN and Orem J and Godfrey C and Hoagland B and Mwelase N and Langat D and Nyirenda M and MacRae J and Borok M and Samaneka W and Moses A and Mngqbisa R and Busakhala N and Martｾｽｭnez-Maza O and Ambinder R and Dittmer DP and Nokta M and Campbell TB,https://pubmed.ncbi.nlm.nih.gov/29365083/,29365083
417,Inclusion,,Phase 3,NCT02151981,AURA3,Non-small cell lung cancer,PFS,Yes,Investigator + central,No protocol,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Only investigator,No protocol,Only investigator,Investigator + central,Central or local in advance but both in paper,,,Non-blinded + blinded,,,FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.,The oncologist,5.03,2018,Odogwu L and Mathieu L and Goldberg KB and Blumenthal GM and Larkins E and Fiero MH and Rodriguez L and Bijwaard K and Lee EY and Philip R and Fan I and Donoghue M and Keegan P and McKee A and Pazdur R,https://pubmed.ncbi.nlm.nih.gov/29242281/,29242281
418,Inclusion,,Phase 2,NCT01839487,HALO 202,Pancreatic cancer,PFS and AE,Yes,Investigator + central,Investigator + central,Investigator + central,Only central,Suspicious of selective reporting,Contradiction,PFS was defined by central radiologic determination or by clinical progression determined by Investigator.,Only blinded,No,Unclear,Only central,Only central,Only central,Consistent,,,Only blinded,,,"HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2018,Hingorani SR and Zheng L and Bullock AJ and Seery TE and Harris WP and Sigal DS and Braiteh F and Ritch PS and Zalupski MM and Bahary N and Oberstein PE and Wang-Gillam A and Wu W and Chondros D and Jiang P and Khelifa S and Pu J and Aldrich C and Hendifar AE,https://pubmed.ncbi.nlm.nih.gov/29232172/,29232172
419,Inclusion,,Phase 2,NCT01746225,SNAP,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2018,Gennari A and Sun Z and Hasler-Strub U and Colleoni M and Kennedy MJ and Von Moos R and Cortｾｽｩs J and Vidal MJ and Hennessy B and Walshe J and Parraga KA and Ribi K and Bernhard J and Murillo SM and Pagani O and Barbeaux A and Borstnar S and Rabaglio-Poretti M and Maibach R and Regan MM and Jerusalem G,https://pubmed.ncbi.nlm.nih.gov/29228091/,29228091
428,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.,Neuro-oncology,12.3,2018,Omuro A and Vlahovic G and Lim M and Sahebjam S and Baehring J and Cloughesy T and Voloschin A and Ramkissoon SH and Ligon KL and Latek R and Zwirtes R and Strauss L and Paliwal P and Harbison CT and Reardon DA and Sampson JH,https://pubmed.ncbi.nlm.nih.gov/29106665/,29106665
429,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.,JAMA oncology,31.78,2018,Seligmann JF and Hatch AJ and Richman SD and Elliott F and Jacobs B and Brown S and Hurwitz H and Barrett JH and Quirke P and Nixon AB and Seymour MT,https://pubmed.ncbi.nlm.nih.gov/29075780/,29075780
432,Inclusion,,Phase 2,NCT00976573,Alliance,Melanoma,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab遯ｶ蜿ｯｽｱ遯ｶ蠖ｱverolimus for metastatic melanoma.",Cancer,6.86,2018,McWilliams RR and Allred JB and Slostad JA and Katipamula R and Dronca RS and Rumilla KM and Erickson LA and Bryce AH and Joseph RW and Kottschade LA and King DM and Leitch JM and Markovic SN,https://pubmed.ncbi.nlm.nih.gov/29044496/,29044496
433,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.,Drug safety,5.61,2018,Kato T and Seto T and Nishio M and Goto K and Yamamoto N and Okamoto I and Tao L and Yu W and Khaznadar T and Tajima K and Shibata M and Seki A and Yamamoto N,https://pubmed.ncbi.nlm.nih.gov/29043496/,29043496
438,Inclusion,,Phase 2,2011-000900-16,AxiG,Glioblastoma,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Unclear,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.,Journal of neuro-oncology,4.13,2018,Duerinck J and Du Four S and Bouttens F and Andre C and Verschaeve V and Van Fraeyenhove F and Chaskis C and D'Haene N and Le Mercier M and Rogiers A and Michotte A and Salmon I and Neyns B,https://pubmed.ncbi.nlm.nih.gov/28988341/,28988341
440,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.,Anticancer research,2.48,2017,He K and Wang X and Guan X and Yu Q and Ma Q and Liu Z and Yu Z,https://pubmed.ncbi.nlm.nih.gov/28982882/,28982882
442,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2017,Mok TSK and Kim SW and Wu YL and Nakagawa K and Yang JJ and Ahn MJ and Wang J and Yang JC and Lu Y and Atagi S and Ponce S and Shi X and Rukazenkov Y and Haddad V and Thress KS and Soria JC,https://pubmed.ncbi.nlm.nih.gov/28968167/,28968167
447,Inclusion,,Phase 3,NCT01719536,CONVINCE,Non-small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Investigator + central,Unclear in advance but clear in paper,,,"Probably, non-blinded + blinded",No ORR,Unclear,No protocol,Unclear,No ORR,Suspicious of selective reporting,Contradiction,ORR was planned to assess in the registry.,No ORR,,,"First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2017,Shi YK and Wang L and Han BH and Li W and Yu P and Liu YP and Ding CM and Song X and Ma ZY and Ren XL and Feng JF and Zhang HL and Chen GY and Han XH and Wu N and Yao C and Song Y and Zhang SC and Song W and Liu XQ and Zhao SJ and Lin YC and Ye XQ and Li K and Shu YQ and Ding LM and Tan FL and Sun Y,https://pubmed.ncbi.nlm.nih.gov/28945850/,28945850
454,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.,Scientific reports,4.38,2017,Passardi A and Scarpi E and Gelsomino F and Palladino MA and Casadei Gardini A and Turci D and Chiuri VE and Mucciarini C and Tassinari D and Ragazzini A and Frassineti GL and Valgiusti M and Ulivi P and Amadori D,https://pubmed.ncbi.nlm.nih.gov/28874797/,28874797
455,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen).,Anticancer research,2.48,2017,Schinzari G and Rossi E and Mambella G and Strippoli A and Cangiano R and Mutignani M and Basso M and Cassano A and Barone C,https://pubmed.ncbi.nlm.nih.gov/28870954/,28870954
464,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.,"European journal of cancer (Oxford, England : 1990)",9.16,2017,Marino P and Sfumato P and Joly F and Fizazi K and Oudard S and Culine S and Habibian M and Boher JM and Gravis G,https://pubmed.ncbi.nlm.nih.gov/28780479/,28780479
465,Exclusion,Study design,,,,,,,,,,,,,,,,,,,,,,,,,,"Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.",The Lancet. Oncology,41.32,2017,Duchesne GM and Woo HH and King M and Bowe SJ and Stockler MR and Ames A and D'Este C and Frydenberg M and Loblaw A and Malone S and Millar J and Tai KH and Turner S,https://pubmed.ncbi.nlm.nih.gov/28760403/,28760403
474,Inclusion,,Phase 2,NCT01685255,No name,Ovarian cancer,PFS,Yes,Investigator + central,No protocol,Investigator + central,Only investigator,Suspicious of selective reporting,Contradiction,PFS was planned to assess in the regstry.,Only non-blinded,No ORR,No ORR,No protocol,No ORR,No ORR,Consistent,,,No ORR,,,"A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.",Gynecologic oncology,5.48,2017,Kristeleit R and Davidenko I and Shirinkin V and El-Khouly F and Bondarenko I and Goodheart MJ and Gorbunova V and Penning CA and Shi JG and Liu X and Newton RC and Zhao Y and Maleski J and Leopold L and Schilder RJ,https://pubmed.ncbi.nlm.nih.gov/28698009/,28698009
478,Inclusion,,Phase 2,NCT01585987,No name,Stomach cancer,immune-related progression-free survival (irPFS),No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only blinded",No ORR,No ORR,No protocol,No ORR,No ORR,Consistent,,,No ORR,,,Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.,Clinical cancer research : an official journal of the American Association for           Cancer Research,12.53,2017,Bang YJ and Cho JY and Kim YH and Kim JW and Di Bartolomeo M and Ajani JA and Yamaguchi K and Balogh A and Sanchez T and Moehler M,https://pubmed.ncbi.nlm.nih.gov/28655793/,28655793
483,Exclusion,Outcome,,,,,,,,,,,,,,,,,,,,,,,,,,Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.,"European journal of cancer (Oxford, England : 1990)",9.16,2017,Pivot X and Spano JP and Espie M and Cottu P and Jouannaud C and Pottier V and Moreau L and Extra JM and Lortholary A and Rivera P and Spaeth D and Attar-Rabia H and Benkanoun C and Dima-Martinez L and Esposito N and Gligorov J,https://pubmed.ncbi.nlm.nih.gov/28648618/,28648618
485,Inclusion,,Phase 2b,NCT01810393,No name,Esophageal Cancer,PFS and ORR,Yes,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",Yes,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only non-blinded",,,"Efficacy and safety of recombinant human lymphotoxin-ｾ趣ｽｱ derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.",Cancer,6.86,2017,Wang FH and Wang Y and Sun GP and Chen JH and Lin YC and Liu W and Zheng RS and Chen J and Zhang HL and Lan HT and Qi J and Liu YQ and Deng YM and Zhao H and Xiong JP and Xu Q and Jiang WQ and Li YH,https://pubmed.ncbi.nlm.nih.gov/28640389/,28640389
488,Inclusion,,Phase 2,NCT01139775,No name,Non-small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Only investigator,No protocol,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",,,"A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.","Lung cancer (Amsterdam, Netherlands)",5.71,2017,Wehler T and Thomas M and Schumann C and Bosch-Barrera J and Viｾｽｱolas Segarra N and Dickgreber NJ and Dalhoff K and Sebastian M and Corral Jaime J and Alonso M and Hynes SM and Lin J and Hurt K and Bence Lin A and Calvo E and Paz-Ares L,https://pubmed.ncbi.nlm.nih.gov/28625637/,28625637
492,Inclusion,,Phase 3,NCT01828112,ASCEND-5,Non-small cell lung cancer,PFS,Yes,Only central,No protocol,Only central,Investigator + central,Central or local in advance but both in paper,,,Non-blinded + blinded,No,Only central,No protocol,Only central,Investigator + central,Central or local in advance but both in paper,,,Non-blinded + blinded,,,"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.",The Lancet. Oncology,41.32,2017,Shaw AT and Kim TM and Crinｾｽｲ L and Gridelli C and Kiura K and Liu G and Novello S and Bearz A and Gautschi O and Mok T and Nishio M and Scagliotti G and Spigel DR and Deudon S and Zheng C and Pantano S and Urban P and Massacesi C and Viraswami-Appanna K and Felip E,https://pubmed.ncbi.nlm.nih.gov/28602779/,28602779
494,Inclusion,,Phase 3,NCT02000622,OlympiAD,Breast cancer,PFS,Yes,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Only central,Only central,Only central,Only central,Consistent,,,Only blinded,,,Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.,The New England journal of medicine,91.25,2017,Robson M and Im SA and Senkus E and Xu B and Domchek SM and Masuda N and Delaloge S and Li W and Tung N and Armstrong A and Wu W and Goessl C and Runswick S and Conte P,https://pubmed.ncbi.nlm.nih.gov/28578601/,28578601
497,Inclusion,,Phase 2,NCT01767194,COG ANBL1221,Neuroblastoma,ORR,No,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,Only blinded,Yes,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,Only blinded,,,"Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.",The Lancet. Oncology,41.32,2017,Mody R and Naranjo A and Van Ryn C and Yu AL and London WB and Shulkin BL and Parisi MT and Servaes SE and Diccianni MB and Sondel PM and Bender JG and Maris JM and Park JR and Bagatell R,https://pubmed.ncbi.nlm.nih.gov/28549783/,28549783
506,Inclusion,,Phase 2,NCT00819780,PEAK,Colorectal cancer,PFS,Yes,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.,International journal of colorectal disease,2.57,2017,Rivera F and Karthaus M and Hecht JR and Sevilla I and Forget F and Fasola G and Canon JL and Guan X and Demonty G and Schwartzberg LS,https://pubmed.ncbi.nlm.nih.gov/28424871/,28424871
507,Inclusion,,Phase 2/3,NCT01830231,SECAVIN,Urothelial cancer,ORR,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2017,Bellmunt J and Kerst JM and Vｾｽ｡zquez F and Morales-Barrera R and Grande E and Medina A and Gonzｾｽ｡lez Graguera MB and Rubio G and Anido U and Fernｾｽ｡ndez Calvo O and Gonzｾｽ｡lez-Billalabeitia E and Van den Eertwegh AJM and Pujol E and Perez-Gracia JL and Gonzｾｽ｡lez Larriba JL and Collado R and Los M and Maciｾｽ｡ S and De Wit R,https://pubmed.ncbi.nlm.nih.gov/28419193/,28419193
510,Inclusion,,Phase 2,NCT01529411,MAJA,Urothelial cancer,PFS,Yes,Unclear,No protocol,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,No ORR,No protocol,No ORR,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,"Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.",The Lancet. Oncology,41.32,2017,Garcｾｽｭa-Donas J and Font A and Pｾｽｩrez-Valderrama B and Virizuela JA and Climent Mｾ and Hernando-Polo S and Arranz Jｾ and Del Mar Llorente M and Lainez N and Villa-Guzmｾｽ｡n JC and Mellado B and Gonzｾｽ｡lez Del Alba A and Castellano D and Gallardo E and Anido U and Garcｾｽｭa Del Muro X and Domｾｽｨnech M and Puente J and Morales-Barrera R and Pｾｽｩrez-Gracia JL and Bellmunt J,https://pubmed.ncbi.nlm.nih.gov/28389316/,28389316
512,Inclusion,,Phase 2,EudraCT 2011-002172-16,No name,Pancreatic cancer,ORR,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,No ORR,No protocol,No ORR,Unclear,Unclear in advance but clear in paper,,,"Probably, only non-blinded",,,Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2017,Poveda A and Del Campo JM and Ray-Coquard I and Alexandre J and Provansal M and Guerra Alｾｽｭa EM and Casado A and Gonzalez-Martin A and Fernｾｽ｡ndez C and Rodriguez I and Soto A and Kahatt C and Fernｾｽ｡ndez Teruel C and Galmarini CM and Pｾｽｩrez de la Haza A and Bohan P and Berton-Rigaud D,https://pubmed.ncbi.nlm.nih.gov/28368437/,28368437
514,Inclusion,,Phase 3,Not available,No name,GI stromal tumors (GISTs),PFS,Yes,No registry,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,No registry,Unclear,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2017,Casali PG and Zalcberg J and Le Cesne A and Reichardt P and Blay JY and Lindner LH and Judson IR and Schｾｽｶffski P and Leyvraz S and Italiano A and Grｾｽｼnwald V and Pousa AL and Kotasek D and Sleijfer S and Kerst JM and Rutkowski P and Fumagalli E and Hogendoorn P and Litiｾｽｨre S and Marreaud S and van der Graaf W and Gronchi A and Verweij J,https://pubmed.ncbi.nlm.nih.gov/28362562/,28362562
522,Inclusion,,Phase 3,Not available,No name,Testicular cancer,CT assessed lung toxicity,No,No registry,No protocol,Not available,Only central,Unclear in advance but clear in paper,,,Only blinded,No ORR,No registry,No protocol,Not available,No ORR,Not prespecified,,,No ORR,,,"A randomized phase III study of 72遯ｶ譬 infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).",Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2017,Shamash J and Sarker SJ and Huddart R and Harland S and Joffe JK and Mazhar D and Birtle A and White J and Chowdhury K and Wilson P and Marshall MR and Vinnicombe S,https://pubmed.ncbi.nlm.nih.gov/28327896/,28327896
526,Inclusion,,Phase 3,NCT01763164,NEMO,Melanoma,PFS,Yes,Unclear,No protocol,Unclear,Investigator + central,Unclear in advance but clear in paper,,,Non-blinded + blinded,No,Unclear,No protocol,Unclear,Only central,Unclear in advance but clear in paper,,,Only blinded,,,"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.",The Lancet. Oncology,41.32,2017,Dummer R and Schadendorf D and Ascierto PA and Arance A and Dutriaux C and Di Giacomo AM and Rutkowski P and Del Vecchio M and Gutzmer R and Mandala M and Thomas L and Demidov L and Garbe C and Hogg D and Liszkay G and Queirolo P and Wasserman E and Ford J and Weill M and Sirulnik LA and Jehl V and Bozｾｽｳn V and Long GV and Flaherty K,https://pubmed.ncbi.nlm.nih.gov/28284557/,28284557
530,Inclusion,,Phase 2,NCT01439568,No name,Small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.,"Lung cancer (Amsterdam, Netherlands)",5.71,2017,Salgia R and Stille JR and Weaver RW and McCleod M and Hamid O and Polzer J and Roberson S and Flynt A and Spigel DR,https://pubmed.ncbi.nlm.nih.gov/28236984/,28236984
531,Inclusion,,Phase 2,NCT01295827,MK3475-P001 (P001),Melanoma,ORR,No PFS,Investigator + central,No protocol,Investigator + central,No PFS,Suspicious of selective reporting,Contradiction,PFS and ORR were planned to assess in the registry.,No PFS,Yes,Investigator + central,No protocol,Investigator + central,Only central,Suspicious of selective reporting,Contradiction,PFS and ORR were planned to assess in the registry.,Only blinded,,,FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.,Clinical cancer research : an official journal of the American Association for           Cancer Research,12.53,2017,Chuk MK and Chang JT and Theoret MR and Sampene E and He K and Weis SL and Helms WS and Jin R and Li H and Yu J and Zhao H and Zhao L and Paciga M and Schmiel D and Rawat R and Keegan P and Pazdur R,https://pubmed.ncbi.nlm.nih.gov/28235882/,28235882
532,Inclusion,,Phase 2b,NCT01303029,No name,Pancreatic cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.,"European journal of cancer (Oxford, England : 1990)",9.16,2017,Irigoyen A and Gallego J and Guillｾｽｩn Ponce C and Vera R and Iranzo V and Ales I and Arｾｽｩvalo S and Pisa A and Martｾｽｭn M and Salud A and Falcｾｽｳ E and Sｾｽ｡enz A and Manzano Mozo JL and Pulido G and Martｾｽｭnez Galｾｽ｡n J and Pazo-Cid R and Rivera F and Garcｾｽｭa Garcｾｽｭa T and Serra O and Fernｾｽ｡ndez Parra EM and Hurtado A and Gｾｽｳmez Reina MJ and Lｾｽｳpez Gomez LJ and Martｾｽｭnez Ortega E and Benavides M and Aranda E,https://pubmed.ncbi.nlm.nih.gov/28222309/,28222309
533,Inclusion,,Phase 2,NCT01234402,No name,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.,The oncologist,5.03,2017,Vahdat LT and Layman R and Yardley DA and Gradishar W and Salkeni MA and Joy AA and Garcia AA and Ward P and Khatcheressian J and Sparano J and Rodriguez G and Tang S and Gao L and Dalal RP and Kauh J and Miller K,https://pubmed.ncbi.nlm.nih.gov/28220020/,28220020
534,Inclusion,,Phase 2,NCT01446731,No name,Prostate cancer,immune response,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,No ORR,No protocol,No ORR,Unclear,Unclear in advance but clear in paper,,,"Probably, only non-blinded",,,Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.,Cytotherapy,5.41,2017,Kongsted P and Borch TH and Ellebaek E and Iversen TZ and Andersen R and Met ｾ and Hansen M and Lindberg H and Sengelｾｽｸv L and Svane IM,https://pubmed.ncbi.nlm.nih.gov/28215654/,28215654
536,Inclusion,,Phase 3,NCT02253459,No name,Breast cancer,PFS,Yes,Unclear,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Unclear,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,,,"Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.",The Lancet. Oncology,41.32,2017,Zhang P and Sun T and Zhang Q and Yuan Z and Jiang Z and Wang XJ and Cui S and Teng Y and Hu XC and Yang J and Pan H and Tong Z and Li H and Yao Q and Wang Y and Yin Y and Sun P and Zheng H and Cheng J and Lu J and Zhang B and Geng C and Liu J and Peng R and Yan M and Zhang S and Huang J and Tang L and Qiu R and Xu B,https://pubmed.ncbi.nlm.nih.gov/28209298/,28209298
538,Inclusion,,Phase 2,NCT01835158,A031203 CABOSUN,Renal cell cancer,PFS,Yes,Investigator + central,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,No,Only investigator,Unclear,Unclear,Only investigator,Unclear in advance but clear in paper,,,Only non-blinded,,,Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2017,Choueiri TK and Halabi S and Sanford BL and Hahn O and Michaelson MD and Walsh MK and Feldman DR and Olencki T and Picus J and Small EJ and Dakhil S and George DJ and Morris MJ,https://pubmed.ncbi.nlm.nih.gov/28199818/,28199818
544,Inclusion,,Phase 3,NCT01828099,ASCEND-4,Non-small cell lung cancer,PFS,Yes,Only central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,No,Investigator + central,Investigator + central,Investigator + central,Investigator + central,Consistent,,,Non-blinded + blinded,,,"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.","Lancet (London, England)",79.32,2017,Soria JC and Tan DSW and Chiari R and Wu YL and Paz-Ares L and Wolf J and Geater SL and Orlov S and Cortinovis D and Yu CJ and Hochmair M and Cortot AB and Tsai CM and Moro-Sibilot D and Campelo RG and McCulloch T and Sen P and Dugan M and Pantano S and Branle F and Massacesi C and de Castro G Jr,https://pubmed.ncbi.nlm.nih.gov/28126333/,28126333
545,Inclusion,,Phase 3,NCT01470742,No name,Stomach cancer,OS,No,No PFS,No protocol,No PFS,Unclear,Not prespecified,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.",Journal of geriatric oncology,3.6,2017,Hwang IG and Ji JH and Kang JH and Lee HR and Lee HY and Chi KC and Park SW and Lee SJ and Kim ST and Lee J and Park SH and Park JO and Park YS and Lim HY and Kang WK,https://pubmed.ncbi.nlm.nih.gov/28119041/,28119041
551,Inclusion,,Phase 2,Not available,No name,Pancreatic cancer,PFS,Yes,No registry,No protocol,Not available,Only central,Unclear in advance but clear in paper,,,"Probably, only blinded",No,No registry,No protocol,Not available,Unclear,Not prespecified,,,"Probably, only blinded",,,Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.,British journal of cancer,7.64,2017,Ioka T and Komatsu Y and Mizuno N and Tsuji A and Ohkawa S and Tanaka M and Iguchi H and Ishiguro A and Kitano M and Satoh T and Yamaguchi T and Takeda K and Kida M and Eguchi K and Ito T and Munakata M and Itoi T and Furuse J and Hamada C and Sakata Y,https://pubmed.ncbi.nlm.nih.gov/28081543/,28081543
553,Inclusion,,Phase 2,NCT01239342,No name,Renal cell cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2017,Jonasch E and Hasanov E and Corn PG and Moss T and Shaw KR and Stovall S and Marcott V and Gan B and Bird S and Wang X and Do KA and Altamirano PF and Zurita AJ and Doyle LA and Lara PN Jr and Tannir NM,https://pubmed.ncbi.nlm.nih.gov/28049139/,28049139
556,Inclusion,,Phase 3,NCT00004935,SAKK 22/99,Breast cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.,Annals of oncology : official journal of the European Society for Medical Oncology,32.98,2017,Pagani O and Klingbiel D and Ruhstaller T and Nolｾｽｨ F and Eppenberger S and Oehlschlegel C and Bernhard J and Brauchli P and Hess D and Mamot C and Munzone E and Pestalozzi B and Rabaglio M and Aebi S and Ribi K and Rochlitz C and Rothgiesser K and Thｾｽｼrlimann B and von Moos R and Zaman K and Goldhirsch A,https://pubmed.ncbi.nlm.nih.gov/27998961/,27998961
558,Inclusion,,Phase 2,NCT02903498,No name,Stomach cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No ORR,No ORR,No protocol,No ORR,No ORR,Consistent,,,No ORR,,,Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.,Oncotarget,3.77,2017,Li W and Zhao X and Wang H and Liu X and Zhao X and Huang M and Qiu L and Zhang W and Chen Z and Guo W and Li J and Zhu X,https://pubmed.ncbi.nlm.nih.gov/27980221/,27980221
559,Inclusion,,Phase 3,NCT02008227,OAK,Non-small cell lung cancer,OS,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.","Lancet (London, England)",79.32,2017,Rittmeyer A and Barlesi F and Waterkamp D and Park K and Ciardiello F and von Pawel J and Gadgeel SM and Hida T and Kowalski DM and Dols MC and Cortinovis DL and Leach J and Polikoff J and Barrios C and Kabbinavar F and Frontera OA and De Marinis F and Turna H and Lee JS and Ballinger M and Kowanetz M and He P and Chen DS and Sandler A and Gandara DR,https://pubmed.ncbi.nlm.nih.gov/27979383/,27979383
565,Inclusion,,Phase 2,NCT00950365,No name,Small cell lung cancer,PFS,Yes,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",,,"Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.",Clinical lung cancer,4.79,2017,Li T and Piperdi B and Walsh WV and Kim M and Beckett LA and Gucalp R and Haigentz M Jr and Bathini VG and Wen H and Zhou K and Pasquinelli PB and Gajavelli S and Sreedhara M and Xie X and Lara PN Jr and Gandara DR and Perez-Soler R,https://pubmed.ncbi.nlm.nih.gov/27919627/,27919627
569,Inclusion,,Phase 3,NCT00801736,ERCC1,Non-small cell lung cancer,OS,No,Unclear,No protocol,Unclear,Unclear,Consistent: unclear,,,"Probably, only non-blinded",No,No ORR,No protocol,No ORR,Unclear,Unclear in advance but clear in paper,,,"Probably, only non-blinded",,,Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,44.54,2017,Lee SM and Falzon M and Blackhall F and Spicer J and Nicolson M and Chaudhuri A and Middleton G and Ahmed S and Hicks J and Crosse B and Napier M and Singer JM and Ferry D and Lewanski C and Forster M and Rolls SA and Capitanio A and Rudd R and Iles N and Ngai Y and Gandy M and Lillywhite R and Hackshaw A,https://pubmed.ncbi.nlm.nih.gov/27893326/,27893326
575,Inclusion,,Phase 3,NCT00266799,PELICAN,Breast cancer,PFS,Yes,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,No,Only investigator,No protocol,Only investigator,Only investigator,Consistent,,,Only non-blinded,,,A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.,Breast cancer research and treatment,4.87,2017,Harbeck N and Saupe S and Jｾｽ､ger E and Schmidt M and Kreienberg R and Mｾｽｼller L and Otremba BJ and Waldenmaier D and Dorn J and Warm M and Scholz M and Untch M and de Wit M and Barinoff J and Lｾｽｼck HJ and Harter P and Augustin D and Harnett P and Beckmann MW and Al-Batran SE,https://pubmed.ncbi.nlm.nih.gov/27798749/,27798749
579,Inclusion,,Phase 2,Study number: PM 0259 CA 223 B0 ,NorCap-CA223,Breast cancer,DCR,No,Only investigator,No protocol,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",No,Only investigator,No protocol,Only investigator,Unclear,Central or local in advance but unclear in paper,,,"Probably, only non-blinded",,,Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy forｾHER2-Negative Metastatic Breast Cancer.,Clinical breast cancer,3.23,2017,Cinieri S and Chan A and Altundag K and Vandebroek A and Tubiana-Mathieu N and Barnadas A and Dodyk P and Lazzarelli S and Botha M and Rauch D and Villanova G and Coskun U,https://pubmed.ncbi.nlm.nih.gov/27756583/,27756583